GSk在R&D方面取得了进展,已朝着2024年的目标稳步前进。
|
2024年第三季度销售额和核心盈利增长强劲,特殊药品表现出色,有助于抵消疫苗销售下降。
|
|
●
|
总计
2024年第三季度销售额80亿英镑,按实际汇率下降2%;按固定汇率增长2%
|
●
|
疫苗销售
下降15%。 Shingrix 下降7% 和
Arexvy-72%反映ACIP指南变更,美国COVID疫苗优先接种和年度化。 Arexvy 2023年第3季度推出
|
●
|
特种药品销售增加19%。HIV销售增长12%。肿瘤学增长94%。呼吸/免疫和其他增长14%
|
●
|
常规药品销售增长7% 曲来吉剂 +16%
|
●
|
总营业利润下降86%,总每股收益下降100%,主要受到与18亿英镑(23亿美元)相关的一项费用的影响 Zantac 结算
|
●
|
核心营业利润增加5%,核心每股收益增加5%,反映出强劲的特种药品表现,以及有效的成本管理
|
●
|
本季度经营活动产生的现金为25亿英镑,自由现金流为13亿英镑
|
(财务业绩-2024年第三季度结果,除非另有说明,增长率%和评论按照第52页定义的CER计算)。
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年至今
|
||||||||
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
营业额
|
8,012
|
|
(2)
|
|
2
|
|
23,259
|
|
4
|
|
8
|
新冠疫情之外的营业额
|
8,012
|
|
(2)
|
|
2
|
|
23,258
|
|
5
|
|
9
|
总营业利润
|
189
|
|
(90)
|
|
(86)
|
|
3,325
|
|
(46)
|
|
(41)
|
总营业利润率%
|
2.4%
|
|
(21.6个百分点)
|
|
(20.6个百分点)
|
|
14.3%
|
|
(13.4个百分点)
|
|
(12.5个百分点)
|
总每股收益
|
(1.4p)
|
|
>(100)
|
|
(100)
|
|
53.0p
|
|
(53)
|
|
(48)
|
核心
营业利润
|
2,761
|
|
–
|
|
5
|
|
7,717
|
|
10
|
|
16
|
核心
营业利润率 %
|
34.5%
|
|
0.4 百分点
|
|
1.0 百分点
|
|
33.2%
|
|
1.6 百分点
|
|
2.2 百分点
|
核心
每股收益
|
49.7p
|
|
(1)
|
|
5
|
|
136.2p
|
|
8
|
|
14
|
经营活动产生的现金
|
2,499
|
|
–
|
|
|
|
5,275
|
|
19
|
|
|
|
|
研发取得进一步进展,增长前景增强
所有关键治疗领域:
|
|
●
|
传染性
疾病:欧盟批准了 Arexvy 在 50-59 岁的成年人中
风险增加,积极的新数据表明保护已结束
三个呼吸道合胞病毒季节;美国食品药品管理局申请接受格波替达辛
无并发症的尿路感染;bepirovirsen在日本获得SENKU认证
用于慢性乙型肝炎
|
●
|
艾滋病毒:
现实世界的研究表明,99% 的有效性 Apretude, 唯一获批准的长效
HIV PrEP 药物
|
●
|
呼吸/免疫学:
宣布了超长效生物制剂的阳性结果,
depemokimab,用于 ANCHOR 三期试验 (crsWnP)(1) 和完整结果
用于支持申报的 SWIFT-1&2 试验(严重哮喘)
年底前出现严重哮喘和 crsWNP,有双重适应症
可能在 2025 年推出。公布了积极的头条结果
三期 MATINEE 试验 努卡拉 在慢性阻塞性肺病中 努卡拉 在日本批准用于
crsWnp
|
●
|
肿瘤学:扩展
美国食品药品管理局批准了 Jemperli 在子宫内膜癌中;
Blenrep 在美国、欧盟和
日本并在中国获得突破性疗法称号;美国
美国食品药品管理局认定为 GSK5764227(靶向 b7-H3)的突破性疗法
小细胞肺癌中的抗体(药物偶联物)
|
2024年业绩指导确认;宣布2024年第三季度15便士的股息
并继续预计全年60便士的股息:
|
|
●
|
2024年
营业额增长7%至9%;核心营业利润增长11%至
13%;核心每股收益增长10%至12%。预计将在现有范围的
中间水平左右提供业绩表现
|
Emma Walmsley,GSK首席执行官:
“我们实现了又一个季度的销售和核心营业利润增长,并在研发方面取得了进一步良好的进展。专科药品的强劲增长有助于抵消疫苗销售的下降,并反映出我们在肿瘤学和艾滋病领域成功推出新产品的成果,以及我们现在构建的GSK产品组合和业绩的弹性。我们的研发管线继续加强,今年迄今已报告了11项积极的III期临床试验,我们目前正在计划明年推出5个主要新产品的获批机会: Blenrep,Depemokimab, 这是对Nucala的第三个指示 COPD用药,Gepotidacin,以及我们的新型预防脑膜炎疫苗(MenABCWY)。我们还在本季度解决了绝大部分 Zantac诉讼,以消除不确定性,使我们能够更好地关注未来。所有这些意味着我们正朝着实现2024年预期目标的方向前进,我们对2026年和2031年的前景更加有信心。”
|
|
|
|
所有板块的指引均不包括COVID-19解决方案的贡献
|
确认2024年经常汇率下的指引
|
之前的2024年经常汇率下的指引
|
营业额
|
增长在7%至9%之间
|
增长在7%至9%之间
|
核心
营业利润
|
增长在11%至13%之间
|
增长在11%至13%之间
|
核心每股收益
|
增长在10%至12%之间
|
增长在10%至12%之间
|
|
|
|
所有营业额预期都不包括COVID-19解决方案的贡献
|
修订后的2024年指导原则按地区修正
|
之前的2024年指导原则按地区修正
|
生物-疫苗
|
营业额降低个位数百分比
|
营业额增长个位数到中位数百分比
|
专业医药
|
营业额增长高十几个百分比
|
营业额增长百分之中到高十位数
|
一般药品
|
营业额增长百分之中的个位数
|
营业额增长百分之低到中的个位数
|
|
表现:
营业额
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
Q3
2024
|
|
年至今
|
||||||||
|
£百万
|
|
增长
AER%
|
|
增长
比率
|
|
£百万
|
|
增长
地域板块AER%
|
|
增长
比率
|
带状疱疹
|
739
|
|
(10)
|
|
(7)
|
|
2,516
|
|
(1)
|
|
2
|
脑膜炎
|
520
|
|
18
|
|
22
|
|
1,142
|
|
16
|
|
20
|
RSV
(Arexvy)
|
188
|
|
(73)
|
|
(72)
|
|
432
|
|
(39)
|
|
(37)
|
流感
|
283
|
|
(24)
|
|
(22)
|
|
303
|
|
(26)
|
|
(23)
|
已建立
疫苗
|
920
|
|
6
|
|
10
|
|
2,533
|
|
2
|
|
5
|
COVID疫苗
|
2,650
|
|
(18)
|
|
(15)
|
|
6,926
|
|
(3)
|
|
–
|
大流行
疫苗
|
–
|
|
(100)
|
|
>(100)
|
|
–
|
|
(100)
|
|
(100)
|
疫苗
|
2,650
|
|
(18)
|
|
(15)
|
|
6,926
|
|
(5)
|
|
(2)
|
艾滋病毒
|
1,750
|
|
8
|
|
12
|
|
5,120
|
|
10
|
|
13
|
呼吸/免疫及其他
|
843
|
|
10
|
|
14
|
|
2,389
|
|
10
|
|
15
|
肿瘤学
|
373
|
|
86
|
|
94
|
|
1,002
|
|
>100
|
|
>100
|
新冠疫情之外的特种药品
|
2,966
|
|
14
|
|
19
|
|
8,511
|
|
16
|
|
20
|
Xevudy
|
–
|
|
–
|
|
–
|
|
1
|
|
(97)
|
|
(97)
|
特种药品
|
2,966
|
|
14
|
|
19
|
|
8,512
|
|
16
|
|
20
|
呼吸系统
|
1,617
|
|
6
|
|
11
|
|
5,407
|
|
6
|
|
11
|
其他
常规药品
|
779
|
|
(5)
|
|
–
|
|
2,414
|
|
(6)
|
|
(1)
|
常规药品
|
2,396
|
|
3
|
|
7
|
|
7,821
|
|
2
|
|
7
|
总计
|
8,012
|
|
(2)
|
|
2
|
|
23,259
|
|
4
|
|
8
|
总计不含COVID
|
8,012
|
|
(2)
|
|
2
|
|
23,258
|
|
5
|
|
9
|
按
地域板块:
|
|
|
|
|
|
|
|
|
|
|
|
美国
|
4,321
|
|
(5)
|
|
(1)
|
|
12,057
|
|
5
|
|
9
|
欧洲
|
1,618
|
|
4
|
|
6
|
|
4,911
|
|
–
|
|
2
|
国际
|
2,073
|
|
2
|
|
8
|
|
6,291
|
|
6
|
|
12
|
总费用
|
8,012
|
|
(2)
|
|
2
|
|
23,259
|
|
4
|
|
8
|
非COVID期间营业额不包括2020年至2023年的COVID-19解决方案,是一项非IFRS指标,在第52页定义,并与上表中包含的IFRS指标进行对照。财务业绩-Q3 2024年度结果,除非另有说明,增长率%和CER 下的评论。
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2024
|
|
截至目前的年度
|
||||
|
|
£百万
|
AER
|
欧洲碳排放交易体系
|
|
£百万
|
AER
|
欧洲碳排放交易体系
|
疫苗
|
总计
|
2,650
|
(18%)
|
(15%)
|
|
6,926
|
(5%)
|
(2%)
|
不包括COVID
|
2,650
|
(18%)
|
(15%)
|
|
6,926
|
(3%)
|
–%
|
|
|
|
|
|
|
|
|
带状疱疹
|
739
|
(10%)
|
(7%)
|
|
2,516
|
(1%)
|
2%
|
(1)
|
美国人口普查局,国际数据库,2024年数据(2)反映最新的美国人口普查局数据和交货订单(3)美国医疗保险和医疗服务中心
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
脑膜炎
|
520
|
18%
|
22%
|
|
1,142
|
16%
|
20%
|
|
|
|
|
|
|
|
|
RSV
(Arexvy)
|
188
|
(73%)
|
(72%)
|
|
432
|
(39%)
|
(37%)
|
|
|
|
|
|
|
|
|
流感
|
283
|
(24%)
|
(22%)
|
|
303
|
(26%)
|
(23%)
|
|
|
|
|
|
|
|
|
已建立
疫苗
|
920
|
6%
|
10%
|
|
2,533
|
2%
|
5%
|
|
|
|
|
|
|
|
|
|
特种药品
|
总计
|
2,966
|
14%
|
19%
|
|
8,512
|
16%
|
20%
|
不包括COVID
|
2,966
|
14%
|
19%
|
|
8,511
|
16%
|
20%
|
|
|
|
|
|
|
|
|
艾滋病毒
|
1,750
|
8%
|
12%
|
|
5,120
|
10%
|
13%
|
|
|
|
|
|
|
|
|
口服
2DR
|
730
|
13%
|
17%
|
|
2,097
|
17%
|
21%
|
|
|
|
|
|
|
|
|
长效
药物
|
314
|
43%
|
49%
|
|
898
|
54%
|
59%
|
|
|
|
|
|
|
|
|
呼吸/免疫及其他
|
843
|
10%
|
14%
|
|
2,389
|
10%
|
15%
|
(1)
|
美国人口普查局,国际数据库,2024年
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
努卡拉
|
444
|
8%
|
12%
|
|
1,300
|
10%
|
14%
|
|
|
|
|
|
|
|
|
Benlysta
|
389
|
11%
|
16%
|
|
1,067
|
11%
|
15%
|
|
|
|
|
|
|
|
|
肿瘤学
|
373
|
86%
|
94%
|
|
1,002
|
≥100%
|
≥100%
|
|
|
|
|
|
|
|
|
Zejula
|
144
|
3%
|
6%
|
|
450
|
21%
|
25%
|
|
|
|
|
|
|
|
|
常规药品
|
2,396
|
3%
|
7%
|
|
7,821
|
2%
|
7%
|
|
|
|
|
|
|
|
|
呼吸系统
|
1,617
|
6%
|
11%
|
|
5,407
|
6%
|
11%
|
|
|
|
|
|
|
|
|
崔利吉
|
600
|
12%
|
16%
|
|
2,033
|
26%
|
31%
|
|
|
|
|
|
|
|
|
色列替/阿德法
|
218
|
8%
|
13%
|
|
798
|
(8%)
|
(4%)
|
|
|
|
|
|
|
|
|
其他
常规药品
|
779
|
(5%)
|
–%
|
|
2,414
|
(6%)
|
(1%)
|
(1)
|
PARP: 一种聚腺苷二磷酸核糖聚合酶(2)
PD-1: 一种程序性死亡受体-1阻断抗体(3)
JAK1/JAK2 和 ACVR1: 一种每日一次的口服 JAK1/JAK2 和激动素A受体1(ACVR1)抑制剂
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
|||||
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
|
我们
|
总计
|
4,321
|
(5%)
|
(1%)
|
|
12,057
|
5%
|
9%
|
|
不包括 COVID
|
4,321
|
(5%)
|
(1%)
|
|
12,057
|
5%
|
9%
|
|
|
|
|
|
|
|
|
|
欧洲
|
总费用
|
1,618
|
4%
|
6%
|
|
4,911
|
–%
|
2%
|
|
不包括COVID
|
1,618
|
4%
|
6%
|
|
4,911
|
3%
|
5%
|
|
|
|
|
|
|
|
|
|
国际
|
总费用
|
2,073
|
2%
|
8%
|
|
6,291
|
6%
|
12%
|
|
不包括COVID
|
2,073
|
2%
|
8%
|
|
6,290
|
7%
|
13%
|
|
财务
业绩
|
|
|
|
|
|
|
|
|
|
|
|
|
总
结果
|
Q3
2024
|
|
年至今
|
||||||||
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
8,012
|
|
(2)
|
|
2
|
|
23,259
|
|
4
|
|
8
|
销售成本
|
(2,397)
|
|
6
|
|
8
|
|
(6,489)
|
|
6
|
|
8
|
销售、一般及行政费用
|
(3,800)
|
|
66
|
|
72
|
|
(8,352)
|
|
25
|
|
29
|
研发费用
|
(1,459)
|
|
(7)
|
|
(5)
|
|
(4,370)
|
|
5
|
|
7
|
版税收入
|
168
|
|
(46)
|
|
(46)
|
|
463
|
|
(36)
|
|
(36)
|
其他营业收入/(费用)
|
(335)
|
|
|
|
|
|
(1,186)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业利润
|
189
|
|
(90)
|
|
(86)
|
|
3,325
|
|
(46)
|
|
(41)
|
净财务费用
|
(124)
|
|
(22)
|
|
(19)
|
|
(408)
|
|
(16)
|
|
(14)
|
分红
联营企业和联合企业的税后利润/(损失)
和合营企业
|
(1)
|
|
|
|
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税前利润
|
64
|
|
(96)
|
|
(92)
|
|
2,914
|
|
(49)
|
|
(43)
|
|
|
|
|
|
|
|
|
|
|
|
|
税收
|
1
|
|
|
|
|
|
(464)
|
|
|
|
|
税率 %
|
(1.6%)
|
|
|
|
|
|
15.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税后利润
|
65
|
|
(96)
|
|
(91)
|
|
2,450
|
|
(50)
|
|
(45)
|
非控股权益所减少的利润
|
123
|
|
|
|
|
|
289
|
|
|
|
|
股东应占利润/(亏损)
|
(58)
|
|
|
|
|
|
2,161
|
|
|
|
|
|
65
|
|
(96)
|
|
(91)
|
|
2,450
|
|
(50)
|
|
(45)
|
|
|
|
|
|
|
|
|
|
|
|
|
每股盈利/(亏损)
|
(1.4)p
|
|
>(100)
|
|
(100)
|
|
53.0p
|
|
(53)
|
|
(48)
|
财务表现-2024年第三季度结果
除非另有说明,增长百分比和定价汇率下的评论。
|
|
核心
结果
第三季度2024年、第三季度2023年、截至目前的2024年和截至目前的2023年的总体结果和核心结果的对账见于第20、21、23和24页。
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2024
|
|
截至目前的年度
|
||||||||
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
|
£百万
|
|
%
空中速度
|
|
%
国内空速
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
8,012
|
|
(2)
|
|
2
|
|
23,259
|
|
4
|
|
8
|
销售成本
|
(1,921)
|
|
(7)
|
|
(5)
|
|
(5,531)
|
|
–
|
|
1
|
销售、一般及管理费用
|
(2,070)
|
|
(5)
|
|
(2)
|
|
(6,272)
|
|
(3)
|
|
1
|
研究与开发
|
(1,428)
|
|
–
|
|
3
|
|
(4,202)
|
|
6
|
|
8
|
版税收入
|
168
|
|
(46)
|
|
(46)
|
|
463
|
|
(36)
|
|
(36)
|
|
|
|
|
|
|
|
|
|
|
|
|
核心
营业利润
|
2,761
|
|
–
|
|
5
|
|
7,717
|
|
10
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
税前核心利润
|
2,646
|
|
1
|
|
7
|
|
7,320
|
|
12
|
|
18
|
税收
|
(461)
|
|
14
|
|
21
|
|
(1,288)
|
|
26
|
|
33
|
税率 %
|
17.4%
|
|
|
|
|
|
17.6%
|
|
|
|
|
税后核心利润
|
2,185
|
|
(1)
|
|
5
|
|
6,032
|
|
9
|
|
15
|
归属于非控股股东的核心利润
利息
|
157
|
|
|
|
|
|
481
|
|
|
|
|
归属于股东的核心利润
|
2,028
|
|
|
|
|
|
5,551
|
|
|
|
|
|
2,185
|
|
(1)
|
|
5
|
|
6,032
|
|
9
|
|
15
|
每股核心盈利
|
49.7p
|
|
(1)
|
|
5
|
|
136.2p
|
|
8
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
Q3 2024
|
|
截至目前的年度
|
||||
|
|
£百万
|
AER
|
CER
|
|
£百万
|
AER
|
CER
|
销售成本
|
总计
|
2,397
|
6%
|
8%
|
|
6,489
|
6%
|
8%
|
销售额的%
|
29.9%
|
2.0%
|
1.5%
|
|
27.9%
|
0.3%
|
(0.2%)
|
|
核心
|
1,921
|
(7%)
|
(5%)
|
|
5,531
|
–%
|
1%
|
|
销售额的%
|
24.0%
|
(1.5%)
|
(1.9%)
|
|
23.8%
|
(1.1%)
|
(1.5%)
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
销售,一般
和管理
|
总计
|
3,800
|
66%
|
72%
|
|
8,352
|
25%
|
29%
|
占销售额的百分比
|
47.4%
|
19.2%
|
19.1%
|
|
35.9%
|
5.8%
|
5.8%
|
|
核心
|
2,070
|
(5%)
|
(2%)
|
|
6,272
|
(3%)
|
1%
|
|
占销售额的百分比
|
25.8%
|
(1.0%)
|
(1.0%)
|
|
27.0%
|
(1.9%)
|
(2.0%)
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年至今
|
||||
|
|
£百万
|
AER
|
CER
|
|
£百万
|
AER
|
CER
|
研究
&
发展
|
总费用
|
1,459
|
(7%)
|
(5%)
|
|
4,370
|
5%
|
7%
|
销售额的%
|
18.2%
|
(1.1%)
|
(1.4%)
|
|
18.8%
|
–%
|
(0.2%)
|
|
核心
|
1,428
|
–%
|
3%
|
|
4,202
|
6%
|
8%
|
|
销售额的%
|
17.8%
|
0.3%
|
–%
|
|
18.1%
|
0.3%
|
–%
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
特许权使用费
收入
|
总计
|
168
|
(46%)
|
(46%)
|
|
463
|
(36%)
|
(36%)
|
|
核心
|
168
|
(46%)
|
(46%)
|
|
463
|
(36%)
|
(36%)
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年至今
|
||||
|
|
£百万
|
AER
|
CER
|
|
£百万
|
AER
|
CER
|
其他
运营
收入/(支出)
|
总费用
|
(335)
|
9%
|
9%
|
|
(1,186)
|
>(100%)
|
>(100%)
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
运营
利润
|
总计
|
189
|
(90%)
|
(86%)
|
|
3,325
|
(46%)
|
(41%)
|
|
占销售额的百分比
|
2.4%
|
(21.6%)
|
(20.6%)
|
|
14.3%
|
(13.4%)
|
(12.5%)
|
|
核心
|
2,761
|
–%
|
5%
|
|
7,717
|
10%
|
16%
|
|
占销售额的百分比
|
34.5%
|
0.4%
|
1.0%
|
|
33.2%
|
1.6%
|
2.2%
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年至今
|
||||
|
|
£百万
|
AER
|
CER
|
|
£百万
|
AER
|
CER
|
净财务费用
|
总费用
|
124
|
(22%)
|
(19%)
|
|
408
|
(16%)
|
(14%)
|
|
核心
|
114
|
(27%)
|
(24%)
|
|
394
|
(18%)
|
(16%)
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
m 英镑
|
是
|
CER
|
|
m 英镑
|
是
|
CER
|
税收
|
总计
|
(1)
|
> (100%)
|
(95%)
|
|
464
|
(40%)
|
(33%)
|
|
税率%
|
(1.6%)
|
|
|
|
15.9%
|
|
|
|
核心
|
461
|
14%
|
21%
|
|
1,288
|
26%
|
33%
|
|
税率%
|
17.4%
|
|
|
|
17.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年至今
|
||||
|
|
£百万
|
AER
|
CER
|
|
£百万
|
AER
|
CER
|
非控制权益
兴趣
("NCIs")
|
总费用
|
123
|
76%
|
84%
|
|
289
|
(13%)
|
(5%)
|
核心
|
157
|
(7%)
|
(5%)
|
|
481
|
15%
|
20%
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
英镑p
|
是
|
CER
|
|
英镑p
|
是
|
CER
|
每股收益/(亏损)
分享
|
总计
|
(1.4p)
|
> (100%)
|
(100%)
|
|
53.0p
|
(53%)
|
(48%)
|
核心
|
49.7p
|
(1%)
|
5%
|
|
136.2p
|
8%
|
14%
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
年
迄今为止
|
||||
|
|
英镑/英镑p
|
是
|
CER
|
|
英镑/英镑p
|
是
|
CER
|
营业额
|
|
8,012
|
(2%)
|
2%
|
|
23,259
|
4%
|
8%
|
每股收益/(亏损)
分享
|
总计
|
(1.4p)
|
> (100%)
|
(100%)
|
|
53.0p
|
(53%)
|
(48%)
|
核心
|
49.7p
|
(1%)
|
5%
|
|
136.2p
|
8%
|
14%
|
|
现金流生成
|
|
|
|
|
|
|
|
|
现金
流动
|
|||||||
|
Q3
2024
£百万
|
|
Q3
2023
£百万
|
|
2024年9
月
£百万
|
|
2023年9
月
£百万
|
经营活动产生的现金流量(百万英镑)
|
2,499
|
|
2,508
|
|
5,275
|
|
4,415
|
从经营活动中产生的净现金流量(百万英镑)
|
2,154
|
|
2,212
|
|
4,225
|
|
3,572
|
自由现金流入/流出*(百万英镑)
|
1,322
|
|
1,655
|
|
1,939
|
|
1,314
|
自由现金流增长率(%)
|
(20%)
|
|
≥100%
|
|
48%
|
|
(41%)
|
自由现金流转换率*(%)
|
≥100%
|
|
≥100%
|
|
90%
|
|
29%
|
总净债务**(百万英镑)
|
12,847
|
|
17,589
|
|
12,847
|
|
17,589
|
*
|
自由现金流和自由现金流转化定义在第52页。自由现金流分析在第43页。
|
**
|
净债务在第43页进行分析。
|
|
|
|
页面
|
2024 年第三季度
管道亮点
|
14
|
ESG
|
16
|
总计
和核心成果
|
18
|
收入
声明
|
26
|
的声明
综合收入
|
27
|
平衡
工作表
|
28
|
的声明
权益变动
|
29
|
现金
流量声明
|
30
|
销售
桌子
|
31
|
分段
信息
|
36
|
合法
事情
|
38
|
退货
致股东
|
39
|
额外
信息
|
40
|
网
债务信息
|
42
|
帖子
资产负债表事件
|
43
|
相关
派对交易
|
43
|
研发
评论
|
44
|
举报
定义
|
52
|
指导和
展望、假设和警示性陈述
|
54
|
独立
审计师向 GsK plc 提交的审查报告
|
55
|
联系方式
|
GSK plc
(伦敦证券交易所/纽约证券交易所:GSK) 是一家全球生物制药公司,旨在结合科学、科技和人才,共同预防疾病。欲了解更多信息,请访问
www.gsk.com.
|
|||
|
|
|
|
GSK
咨询:
|
|
|
|
媒体
|
tim
Foley
|
+44 (0)
20 8047 5502
|
(伦敦)
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(华盛顿)
|
|
|
|
|
投资者关系
|
安娜贝尔
布朗里格-格里森
|
+44 (0)
7901 101944
|
(伦敦)
|
|
詹姆斯
多德韦尔
|
+44 (0)
7881 269066
|
(伦敦)
|
|
米克
雷迪
|
+44 (0)
7990 339653
|
(伦敦)
|
|
杰夫
麦克劳林
|
+1 215
589 3774
|
(费城)
|
|
|
|
|
在英格兰和威尔士注册:
No. 3888792
|
|||
|
|||
注册办公室:
79 新牛津街
伦敦,
WC1A
1DG.
|
2024年第三季度管道亮点(自2024年7月31日起)
|
|
药品/生物-疫苗
|
试验
(指征,展示)
|
2024年6月4日发布的新闻稿。
|
监管
批准或其他监管措施
|
Arexvy
|
RSV,
50-59岁成年人增加风险
|
监管批准
(欧盟)
|
Bexsero
|
脑膜炎
B
|
获得正式监管批准(美国)
|
|
门比奥
|
液体配方,包含脑膜炎ACWY
|
CHMP持积极意见(欧盟)
|
|
努卡拉
|
慢性鼻窦炎伴有鼻息肉
|
获得监管批准(日本)
|
|
Jemperli
|
RUBY
部分 1 (OS 总人口,1L子宫内膜癌)
|
监管批准
(美国)
|
|
监管
提交或接受
|
gepotidacin
|
EAGLE-2/3
(非并发性尿路感染)
|
监管
提交已接受 (美国) 并获优先审查
|
Blenrep
|
DREAMm-7/8 (2L+)
多发性骨髓瘤
|
具有孤儿药和优先审评地位的监管提交被接受(JP)
|
|
III期数据公布或其他重大事件
|
Arexvy
|
RSV,60岁及以上成年人
|
积极的III期数据公布(第三季度)
|
Arexvy
|
RSV,18-49岁的增加风险群体;免疫受损的18岁及以上成年人
|
III期和IIIb阶段的数据公布
|
|
季节性流感生物-疫苗mRNA候选
|
季节性流感,老年人和年轻人
|
积极的II期数据公布
|
|
depemokimab
|
ANCHOR-1/2(慢性鼻窦炎伴有鼻息肉)
|
积极的III期数据公布
|
|
Nucala
|
MATINEE
(慢性阻塞性肺疾病)
|
第三期积极结果
数据结果
|
|
监管
指定和其他重要事件
|
bepirovirsen
|
b-Clear; b-Sure
(慢性乙型肝炎)
|
SENKU
授予的指定(JP)
|
Blenrep
|
DREAMm-7 (2L+
多发性骨髓瘤)
|
突破性治疗认定和优先审查已获批(CN)
|
|
GSK5764227(B7-H3靶向抗体-药物结合物)
|
广泛期-小细胞肺癌
|
突破性治疗认定已获批(US)
|
预期的
资讯流
|
时机
|
药品/疫苗
|
试用
(指示、演示)
|
事件
|
H2
2024
|
Arexvy
|
呼吸道感染,
50-59 岁的成年人风险增加
|
监管决定
(JP)
|
Menveo
|
液体
制剂,脑膜炎 ACWY
|
监管决定
(欧盟)
|
|
depemokimab
|
Swift-1/2(严重
哮喘)
|
监管
提交(美国)
|
|
depemokimab
|
ANCHOR-1/2(慢性)
鼻窦炎(伴有鼻息肉)
|
监管
提交(美国)
|
|
努卡拉
|
日场
(慢性阻塞性肺病)
|
监管
提交(美国)
|
|
Blenrep
|
Dreamm-7/8 (2L +)
多发性骨髓瘤)
|
监管档案
接受(美国)
|
|
Blenrep
|
Dreamm-7 (2L +)
多发性骨髓瘤)
|
监管
提交 (中国)
|
|
泽胡拉
|
第一
(1L 维持性卵巢癌)
|
阶段
III 数据读取
|
|
泽胡拉
|
热情
(1L 维持型非小细胞肺癌)
|
阶段
III 数据读取
|
|
linerixibat
|
闪闪发光
(原发性胆源性胆管炎中的胆汁淤积性瘙痒)
|
阶段
III 数据读取
|
预期的资讯流
持续
|
|
|
|
|
时机
|
药品/疫苗
|
试验(适应症、演示)
|
事件
|
H1
2025
|
Menabcwy
(第 1 代)候选疫苗
|
脑膜炎球菌
ABCWY
|
监管
决定(美国)
|
Shingrix
|
带状疱疹,
18 岁以上的成年人
|
监管
决定 (中国)
|
|
gepotidacin
|
EAGLE-2/3
(无并发症的尿路感染)
|
监管
决定(美国)
|
|
gepotidacin
|
EAGLE-1
(泌尿生殖系统淋病)
|
监管
提交(美国)
|
|
depemokimab
|
Swift-1/2
(严重哮喘)
|
监管
提交
(欧盟,
中国、日本)
|
|
depemokimab
|
锚-1/2
(慢性鼻窦炎伴鼻息肉)
|
监管
提交
(欧盟,
中国、日本)
|
|
depemokimab
|
敏捷
(严重哮喘)
|
阶段
III 数据读取
|
|
努卡拉
|
慢性
鼻窦炎伴鼻息肉
|
监管
决定 (中国)
|
|
努卡拉
|
日场
(慢性阻塞性肺病)
|
监管
决定(美国)
|
|
努卡拉
|
日场
(慢性阻塞性肺病)
|
监管
提交
(中国,
欧盟)
|
|
文托林
|
低
碳 MDI(哮喘)
|
阶段
III 数据读取
|
|
Blenrep
|
Dreamm-7/8
(2L+ 多发性骨髓瘤)
|
监管
决定 (JP)
|
|
cobolimab
|
COSTAR
(非小细胞肺癌)
|
阶段
III 数据读取
|
|
Jemperli
|
红宝石
第 1 部分(操作系统总人口,1L 子宫内膜癌)
|
监管
决定(欧盟)
|
|
linerixibat
|
闪闪发光
(原发性胆源性胆管炎中的胆汁淤积性瘙痒)
|
监管
提交
(我们,
欧盟,中国)
|
|
H2
2025
|
Arexvy
|
呼吸道感染,
18-49 岁的成年人风险增加
|
监管
提交(美国)
|
Bexsero
|
脑膜炎球菌
b(婴儿)
|
阶段
III 数据读出
|
|
Bexsero
|
脑膜炎球菌
b(婴儿)
|
监管
提交(美国)
|
|
gepotidacin
|
EAGLE-1
(泌尿生殖系统淋病)
|
监管
决定(美国)
|
|
gepotidacin
|
EAGLE-J
(无并发症的尿路感染)
|
监管
提交 (JP)
|
|
替比培南
pivoxil
|
Pivot-PO
(复杂的尿路感染)
|
阶段
III 数据读取
|
|
替比培南
pivoxil
|
Pivot-PO
(复杂的尿路感染)
|
监管
提交(美国)
|
|
camlipixant
|
冷静-1/2
(难治性慢性咳嗽)
|
阶段
III 数据读取
|
|
camlipixant
|
冷静-1/2
(难治性慢性咳嗽)
|
监管
提交
(我们,
欧盟)
|
|
depemokimab
|
Swift-1/2
(严重哮喘)
|
监管
决定(美国)
|
|
depemokimab
|
锚-1/2
(慢性鼻窦炎伴鼻息肉)
|
监管
决定(美国)
|
|
depemokimab
|
灵活
(哮喘)
|
阶段
III 数据读取
|
|
文托林
|
低
碳 MDI(哮喘)
|
监管
提交(欧盟)
|
|
Blenrep
|
Dreamm-7/8
(2L+ 多发性骨髓瘤)
|
监管
决定
(我们,
欧盟)
|
|
Blenrep
|
Dreamm-8
(2L + 多发性骨髓瘤)
|
监管
提交 (中国)
|
|
cobolimab
|
联合主演,
(2L 非小细胞肺癌)
|
监管
提交
(我们,
欧盟)
|
|
linerixibat
|
闪闪发光
(原发性胆源性胆管炎中的胆汁淤积性瘙痒)
|
监管
决定(美国)
|
|
linerixibat
|
闪闪发光
(原发性胆源性胆管炎中的胆汁淤积性瘙痒)
|
监管
提交 (JP)
|
请参考页码44至51,了解各个治疗领域正在开发的几种重要药品和疫苗的详细信息。
|
|
|
●
|
在
10 月 ViiV Healthcare 宣布承诺至少做两个
百万剂用于PrEP的洛杉矶CaB可供采购
2025-2026 年期间的低收入和中等收入国家。这个新的
承诺将可用供应量比2024年增加三倍以加速
在艾滋病毒负担和需求未得到满足的地方,获得并满足不断增长的需求
是最伟大的。
|
●
|
ViiV
医疗保健继续取得进展,首款医疗保健的推出
用于 HIV 暴露前预防的长效注射剂(CaB LA for
PrEP)在撒哈拉以南非洲(SSA)和较低收入的地区以创纪录的速度增长
国家。2024 年第三季度,ViiV 开始再推出 2 个
国家-埃斯瓦蒂尼和乌克兰-与我们的全球合作伙伴一起
美国总统的艾滋病紧急救援计划
(PEPFAR)计划。在低收入和低收入人群中推出针对PrEP的洛杉矶CaB
赞比亚于2月开始以非营利价格出售SSA国家
2024 年,距离美国 FDA 批准仅两年,目前是
提供给 5 个国家的关键合作伙伴。
|
●
|
在
九月,葛兰素史克 捐赠(2) 第 120亿
阿苯达唑片剂,将有助于根除
淋巴丝虫病(LF)和土壤传播的治疗
蠕虫(STH)。自 2000 年以来,葛兰素史克一直致力于改变
通过消除LF作为公共卫生问题来发展NTD的轨迹
世界各地。9月底,巴西成为第20个国家
消除 LF 这一公共卫生问题。葛兰素史克为此做出了贡献
通过支持诊断和传播评估
调查。
|
●
|
绩效指标
与访问权限相关的每年更新一次,相关详细信息请参见
葛兰素史克的ESG绩效报告
2023(1) 在页面上
10。
|
|
|
●
|
九月份宣布,全球抗生素研究与开发合作伙伴关系(Gard-P)将在未来三年内向全球投入450万欧元,以确保低收入国家公平获取抗生素。这笔资金旨在解决阻碍急需抗生素的人获得的挑战。更多信息请参阅 这里(3).
|
●
|
九月份,欧盟的IMI2计划TRIC-Tb成功推出了第二阶段准备就绪的肺结核临床候选药物alpibectir,该药物由BioVersys和GSK共同开发。更多信息请参阅 这里(4).
|
●
|
全球健康和健康安全相关的绩效指标每年更新,有关详细信息可以在GSK的2023年ESG绩效报告第15页找到。
|
|
|
●
|
葛兰素史克的
沃辛制造工厂已成为 第一(5) 在英国到
获得 BSI 风筝标志认证,将风险降至最低
抗微生物药物耐药性。实现这一严格的国际化目标
认证表明了葛兰素史克对责任人的承诺
抗生素的制造以及确保全球范围内的目标
抗生素生产场所将在年底前获得认证
2026。
|
●
|
这个
Energize 计划,由 GsK 共同创立并支持
供应商获得可再生能源,宣布了第一笔交易
其中包括葛兰素史克在欧洲的四家供应商,并将
支持西班牙的七个新的太阳能项目,以及
为欧洲电网带来额外的可再生能源产能。这个
标志着我们缩小价值链计划的重要一步
从 2020 年到 2030 年,排放量减少了 80%。
|
●
|
绩效指标
与环境相关的每年更新一次,相关详细信息请参见
葛兰素史克的《2023 年环境、社会及管治绩效报告》第 18 页。
|
|
|
●
|
关于多样性、公平性和包容性的绩效指标每年更新,相关细节可在GSK的ESG绩效报告2023年第26页找到。有关GSK的DEI更多信息可在此查阅。 这里(6).
|
|
|
●
|
绩效指标
与道德标准相关的内容每年更新,相关细节可在GSK的ESG绩效报告2023年第30页找到。
|
|
|
●
|
与产品治理相关的绩效指标每年更新,在GSK的2023年ESG绩效报告第35页有相关详情。
|
|
|
|
|
外部
基准
|
当前
评分/排名
|
旧
评分/排名
|
评论
|
标普全球企业可持续性评估
|
78
|
80
|
当前
分数更新于2024年9月
|
药品准入指数
|
4.06
|
4.23
|
自2008年创立以来一直领先这一半年度指数;每年更新,2022年11月的最新结果
|
抗菌药物抵抗基准
|
84%
|
86%
|
自2018年成立以来一直领先这一半年度基准;2021年11月更新的最新排名
|
CDP气候变化
|
A-
|
A-
|
每年更新,2024年2月更新的当前分数(供应商参与度,2023年3月)
|
CDP水安防
|
A-
|
B
|
|
CDP森林(棕榈油)
|
B
|
A-
|
|
CDP
森林 (木材)
|
B
|
B
|
|
CDP
供应商参与评级
|
领导者
|
领导者
|
|
Sustainalytics
|
15.4
|
16.7
|
在制药行业群体中排名第2百分位;得分越低
代表风险越低。当前排名更新至2024年5月
|
MSCI
|
AA
|
AA
|
最近一次评级行动日期: 2023年9月
|
穆迪esg解决方案
|
62
|
61
|
当前得分已于2023年8月更新
|
ISS企业评级
|
BB- 1.000%
|
BB- 1.000%
|
当前得分已于2024年10月更新
|
FTSE4Good
|
成员
|
成员
|
自2004年成为会员,最新审核于2024年6月
|
ShareAction的劳工披露倡议
|
79%
|
77%
|
当前分数更新至2024年1月
|
(1)
|
https://www.gsk.com/media/11009/esg-performance-report-2023.pdf
|
(2)
|
https://unitingtocombatntds.org/en/news-and-views/zanzibar-marks-historic-milestone-with-12-billionth-medicine-dose-in-fight-against-ntds
|
(3)
|
https://gardp.org/funders-invest-an-unprecedented-eur-60-million-in-innovative-antibiotic-rd-and-access-partnership
|
(4)
|
https://www.bioversys.com/nature-reviews-highlights-significant-successes-of-antibiotic-collaboration-and-calls-for-sustainable-rd-funding-schemes/
|
(5)
|
https://www.bsigroup.com/en-GB/insights-and-media/media-centre/press-releases/2024/september/gsk-site-announced-as-first-in-the-uk-to-achieve-bsi-amr-kitemark-certification-showcasing-responsible-approach-to-antibiotic-manufacturing
|
(6)
|
https://www.gsk.com/en-gb/responsibility/diversity-equity-and-inclusion/
|
|
|
●
|
无形资产的摊销(不包括计算机-半导体软件和资本化的开发成本)
|
●
|
无形资产的减值(不包括计算机-半导体软件)和商誉
|
●
|
主要重组成本,包括有形资产和计算机-半导体软件的减值(在董事会批准的特定项目中,这些项目具有结构性、规模显著,并且个别或相关项目的成本超过£2500万),包括根据实质性收购进行的整合成本
|
●
|
相关交易的会计或其他调整,涉及重大收购
|
●
|
处置联营企业、产品和业务的收益和成本; 重大和解收入; 重大法律费用(扣除保险索赔)和诉讼和政府调查解决时的费用; 除版税收入外的其他营业收入,以及其他项目,包括从外币翻译储备中重新分类到损益表的金额,在子公司清算时,金额超过£2500万
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
总费用
结果
£百万
|
|
无形资产
分期偿还-
投资者-
£百万
|
|
无形资产
impair-
处理
£百万
|
|
主要的
restruct-
uring
£百万
|
|
Trans-
action-
相关的
£百万
|
|
显著的
legal,
Divest-
ments
and
其他
项目
£百万
|
|
核心
结果
£百万
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
8,012
|
|
|
|
|
|
|
|
|
|
|
|
8,012
|
销售成本
|
(2,397)
|
|
402
|
|
|
|
67
|
|
2
|
|
5
|
|
(1,921)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
毛利润
|
5,615
|
|
402
|
|
|
|
67
|
|
2
|
|
5
|
|
6,091
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
销售、一般及行政费用
|
(3,800)
|
|
|
|
|
|
33
|
|
|
|
1,697
|
|
(2,070)
|
研发费用
|
(1,459)
|
|
13
|
|
17
|
|
1
|
|
|
|
|
|
(1,428)
|
版税收入
|
168
|
|
|
|
|
|
|
|
|
|
|
|
168
|
其他营业收入/(费用)
|
(335)
|
|
|
|
|
|
(1)
|
|
359
|
|
(23)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业利润
|
189
|
|
415
|
|
17
|
|
100
|
|
361
|
|
1,679
|
|
2,761
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
净财务费用
|
(124)
|
|
|
|
|
|
1
|
|
|
|
9
|
|
(114)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
分红
联营企业和联合企业的税后利润/(损失)
和合营企业
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税前利润
|
64
|
|
415
|
|
17
|
|
101
|
|
361
|
|
1,688
|
|
2,646
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税收
|
1
|
|
(88)
|
|
(3)
|
|
(22)
|
|
(103)
|
|
(246)
|
|
(461)
|
税率 %
|
(1.6%)
|
|
|
|
|
|
|
|
|
|
|
|
17.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税后利润
|
65
|
|
327
|
|
14
|
|
79
|
|
258
|
|
1,442
|
|
2,185
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
归属于非控股股东的利润
利息
|
123
|
|
|
|
|
|
|
|
34
|
|
|
|
157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
股东应占利润/(亏损)
|
(58)
|
|
327
|
|
14
|
|
79
|
|
224
|
|
1,442
|
|
2,028
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
65
|
|
327
|
|
14
|
|
79
|
|
258
|
|
1,442
|
|
2,185
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
每股收益/(亏损)
|
(1.4)p
|
|
8.0p
|
|
0.3p
|
|
1.9p
|
|
5.5p
|
|
35.4p
|
|
49.7p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
加权平均股数(百万股)
|
4,080
|
|
|
|
|
|
|
|
|
|
|
|
4,080
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
总费用
结果
£百万
|
|
无形资产
分期偿还-
化
£百万
|
|
无形资产
损害-
处理
£百万
|
|
主要的
重组-
uring
£百万
|
|
转-
行动-
相关的
£百万
|
|
显著的
法律,
剥离-
部门
和
其他
项目
£百万
|
|
核心
结果
£百万
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
8,147
|
|
|
|
|
|
|
|
|
|
|
|
8,147
|
销售成本
|
(2,272)
|
|
162
|
|
|
|
29
|
|
|
|
8
|
|
(2,073)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
毛利润
|
5,875
|
|
162
|
|
|
|
29
|
|
|
|
8
|
|
6,074
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
销售、一般及行政费用
|
(2,296)
|
|
|
|
|
|
83
|
|
1
|
|
27
|
|
(2,185)
|
研发费用
|
(1,575)
|
|
20
|
|
129
|
|
(2)
|
|
|
|
(1)
|
|
(1,429)
|
版税收入
|
312
|
|
|
|
|
|
|
|
|
|
|
|
312
|
其他营业收入/(费用)
|
(367)
|
|
|
|
|
|
|
|
576
|
|
(209)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业利润
|
1,949
|
|
182
|
|
129
|
|
110
|
|
577
|
|
(175)
|
|
2,772
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
净财务费用
|
(158)
|
|
|
|
|
|
|
|
|
|
2
|
|
(156)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税前利润
|
1,791
|
|
182
|
|
129
|
|
110
|
|
577
|
|
(173)
|
|
2,616
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税收
|
(257)
|
|
(40)
|
|
(30)
|
|
(19)
|
|
(61)
|
|
3
|
|
(404)
|
税率 %
|
14.3%
|
|
|
|
|
|
|
|
|
|
|
|
15.4%
|
税后利润
|
1,534
|
|
142
|
|
99
|
|
91
|
|
516
|
|
(170)
|
|
2,212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
非控制权益
归属利润
利息
|
70
|
|
|
|
|
|
|
|
99
|
|
|
|
169
|
股东
应占利润
|
1,464
|
|
142
|
|
99
|
|
91
|
|
417
|
|
(170)
|
|
2,043
|
|
1,534
|
|
142
|
|
99
|
|
91
|
|
516
|
|
(170)
|
|
2,212
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
每股收益
|
36.1p
|
|
3.5p
|
|
2.4p
|
|
2.2p
|
|
10.3p
|
|
(4.1)p
|
|
50.4p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
加权平均
股数(百万)
|
4,055
|
|
|
|
|
|
|
|
|
|
|
|
4,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
Q3
2023
|
||||||||
|
现金
£百万
|
|
非公司治理股份
现金
£百万
|
|
总费用
£百万
|
|
现金
£百万
|
|
非公司治理股份
现金
£百万
|
|
总费用
£百万
|
|
|
|
|
|
|
|
|
|
|
|
|
分离
重组计划
|
42
|
|
(2)
|
|
40
|
|
45
|
|
50
|
|
95
|
重大
收购
|
15
|
|
–
|
|
15
|
|
18
|
|
(1)
|
|
17
|
传统
项目
|
45
|
|
–
|
|
45
|
|
(1)
|
|
(1)
|
|
(2)
|
|
102
|
|
(2)
|
|
100
|
|
62
|
|
48
|
|
110
|
|
|
|
|
充值/贷方
|
Q3
2024
£百万
|
|
Q3
2023
£百万
|
辉瑞-维富Healthcare合资公司以前的创业公司的有条件款项
(包括Shionogi优先分红)
|
292
|
|
479
|
维富Healthcare看跌期权和辉瑞优先分红
|
(16)
|
|
40
|
诺华疫苗业务以前的有条件款项
|
46
|
|
(12)
|
Affinivax收购的有条件款项
|
15
|
|
69
|
其他
调整
|
24
|
|
1
|
|
|
|
|
总共
与交易相关的费用
|
361
|
|
577
|
|
|
|||||||||||||
总公司2024年9个月和2023年9个月的财务和核心结果之间的对账如下。
2024年9月30日结束的九个月
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
总费用
结果
£百万
|
|
无形资产
分期偿还-
化
£百万
|
|
无形资产
损害-
处理
£百万
|
|
主要的
重组-
uring
£百万
|
|
转-
行动-
相关的
£百万
|
|
显著的
法律,
剥离-
部门
和
其他
项目
£百万
|
|
核心
结果
£百万
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
23,259
|
|
|
|
|
|
|
|
|
|
|
|
23,259
|
|
销售成本
|
(6,489)
|
|
764
|
|
|
|
141
|
|
40
|
|
13
|
|
(5,531)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
毛利润
|
16,770
|
|
764
|
|
|
|
141
|
|
40
|
|
13
|
|
17,728
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
销售、一般及行政费用
|
(8,352)
|
|
|
|
|
|
125
|
|
1
|
|
1,954
|
|
(6,272)
|
|
研发费用
|
(4,370)
|
|
40
|
|
118
|
|
10
|
|
|
|
|
|
(4,202)
|
|
版税收入
|
463
|
|
|
|
|
|
|
|
|
|
|
|
463
|
|
其他营业收入/(费用)
|
(1,186)
|
|
|
|
|
|
5
|
|
1,422
|
|
(241)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业利润
|
3,325
|
|
804
|
|
118
|
|
281
|
|
1,463
|
|
1,726
|
|
7,717
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
净财务费用
|
(408)
|
|
|
|
|
|
1
|
|
|
|
13
|
|
(394)
|
|
分红
联营企业和联合企业的税后利润/(损失)
和创业公司
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税前利润
|
2,914
|
|
804
|
|
118
|
|
282
|
|
1,463
|
|
1,739
|
|
7,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税收
|
(464)
|
|
(172)
|
|
(28)
|
|
(69)
|
|
(300)
|
|
(255)
|
|
(1,288)
|
|
税率 %
|
15.9%
|
|
|
|
|
|
|
|
|
|
|
|
17.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税后利润
|
2,450
|
|
632
|
|
90
|
|
213
|
|
1,163
|
|
1,484
|
|
6,032
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
非控制权益
归属利润
利息
|
289
|
|
|
|
|
|
|
|
192
|
|
|
|
481
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
股东
应占利润
|
2,161
|
|
632
|
|
90
|
|
213
|
|
971
|
|
1,484
|
|
5,551
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,450
|
|
632
|
|
90
|
|
213
|
|
1,163
|
|
1,484
|
|
6,032
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
每股收益
|
53.0p
|
|
15.5p
|
|
2.2p
|
|
5.2p
|
|
23.8p
|
|
36.5p
|
|
136.2p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
加权平均
股数(百万)
|
4,076
|
|
|
|
|
|
|
|
|
|
|
|
4,076
|
|
九
2023年9月30日结束的九个月
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
总费用
结果
£百万
|
|
无形资产
分期偿还-
化
£百万
|
|
无形资产
损害-
处理
£百万
|
|
主要的
重组-
uring
£百万
|
|
转-
行动-
相关的
£百万
|
|
显著的
legal,
Divest-
部门
和
其他
项目
£百万
|
|
核心
结果
£百万
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业额
|
22,276
|
|
|
|
|
|
|
|
|
|
|
|
22,276
|
销售成本
|
(6,147)
|
|
477
|
|
|
|
97
|
|
|
|
20
|
|
(5,553)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
毛利润
|
16,129
|
|
477
|
|
|
|
97
|
|
|
|
20
|
|
16,723
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
销售、一般及行政费用
|
(6,707)
|
|
|
|
|
|
163
|
|
1
|
|
102
|
|
(6,441)
|
研发费用
|
(4,176)
|
|
58
|
|
149
|
|
4
|
|
|
|
(1)
|
|
(3,966)
|
版税收入
|
718
|
|
|
|
|
|
|
|
|
|
|
|
718
|
其他营业收入/(费用)
|
208
|
|
|
|
|
|
|
|
116
|
|
(324)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
营业利润
|
6,172
|
|
535
|
|
149
|
|
264
|
|
117
|
|
(203)
|
|
7,034
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
净财务费用
|
(484)
|
|
|
|
|
|
1
|
|
|
|
5
|
|
(478)
|
分享
税后利润/(亏损)
联营企业和合营企业
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
(4)
|
对利润/(损失)处分兴趣
与企业合伙人
|
1
|
|
|
|
|
|
|
|
|
|
(1)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税前利润
|
5,685
|
|
535
|
|
149
|
|
265
|
|
117
|
|
(199)
|
|
6,552
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税收
|
(775)
|
|
(116)
|
|
(35)
|
|
(52)
|
|
(29)
|
|
(15)
|
|
(1,022)
|
税率 %
|
13.6%
|
|
|
|
|
|
|
|
|
|
|
|
15.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
税后利润
|
4,910
|
|
419
|
|
114
|
|
213
|
|
88
|
|
(214)
|
|
5,530
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
非控制权益
归属利润
利息
|
332
|
|
|
|
|
|
|
|
88
|
|
|
|
420
|
股东
应占利润
|
4,578
|
|
419
|
|
114
|
|
213
|
|
–
|
|
(214)
|
|
5,110
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,910
|
|
419
|
|
114
|
|
213
|
|
88
|
|
(214)
|
|
5,530
|
每股收益
|
113.0p
|
|
10.3p
|
|
2.8p
|
|
5.3p
|
|
–
|
|
(5.2)p
|
|
126.2p
|
加权平均
股数(百万)
|
4,050
|
|
|
|
|
|
|
|
|
|
|
|
4,050
|
|
Total
Major restructuring charges incurred in nine months ended 30
September 2024 were £281 million (nine months ended 30
September 2023: £264 million), analysed as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9 months 2024
|
|
9
months 2023
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
restructuring programme
|
169
|
|
14
|
|
183
|
|
107
|
|
101
|
|
208
|
Significant
acquisitions
|
50
|
|
1
|
|
51
|
|
54
|
|
1
|
|
55
|
Legacy
programmes
|
47
|
|
–
|
|
47
|
|
1
|
|
–
|
|
1
|
|
266
|
|
15
|
|
281
|
|
162
|
|
102
|
|
264
|
|
|
|
|
Charge/(credit)
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including Shionogi preferential dividends)
|
1,106
|
|
406
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
54
|
|
(203)
|
Contingent
consideration on former Novartis Vaccines business
|
206
|
|
(134)
|
Contingent
consideration on acquisition of Affinivax
|
31
|
|
47
|
Other
adjustments
|
66
|
|
1
|
|
|
|
|
Total
transaction-related charges
|
1,463
|
|
117
|
|
Financial
information
|
Income statement
|
|
Q3
2024
£m
|
|
Q3
2023
£m
|
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
|
|
|
|
|
|
|
TURNOVER
|
8,012
|
|
8,147
|
|
23,259
|
|
22,276
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,397)
|
|
(2,272)
|
|
(6,489)
|
|
(6,147)
|
Gross
profit
|
5,615
|
|
5,875
|
|
16,770
|
|
16,129
|
|
|
|
|
|
|
|
|
Selling, general
and administration
|
(3,800)
|
|
(2,296)
|
|
(8,352)
|
|
(6,707)
|
Research and
development
|
(1,459)
|
|
(1,575)
|
|
(4,370)
|
|
(4,176)
|
Royalty
income
|
168
|
|
312
|
|
463
|
|
718
|
Other
operating income/(expense)
|
(335)
|
|
(367)
|
|
(1,186)
|
|
208
|
|
|
|
|
|
|
|
|
OPERATING
PROFIT
|
189
|
|
1,949
|
|
3,325
|
|
6,172
|
|
|
|
|
|
|
|
|
Finance
income
|
32
|
|
24
|
|
88
|
|
86
|
Finance
expense
|
(156)
|
|
(182)
|
|
(496)
|
|
(570)
|
Share
of after tax profit/(loss) of associates and joint
ventures
|
(1)
|
|
–
|
|
(3)
|
|
(4)
|
Profit/(loss) on
disposal of interests in associates and joint
ventures
|
–
|
|
–
|
|
–
|
|
1
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAXATION
|
64
|
|
1,791
|
|
2,914
|
|
5,685
|
|
|
|
|
|
|
|
|
Taxation
|
1
|
|
(257)
|
|
(464)
|
|
(775)
|
Tax rate %
|
(1.6%)
|
|
14.3%
|
|
15.9%
|
|
13.6%
|
|
|
|
|
|
|
|
|
PROFIT
AFTER TAXATION
|
65
|
|
1,534
|
|
2,450
|
|
4,910
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
123
|
|
70
|
|
289
|
|
332
|
Profit/(loss)
attributable to shareholders
|
(58)
|
|
1,464
|
|
2,161
|
|
4,578
|
|
65
|
|
1,534
|
|
2,450
|
|
4,910
|
|
|
|
|
|
|
|
|
EARNINGS/(LOSS)
PER SHARE
|
(1.4)p
|
|
36.1p
|
|
53.0p
|
|
113.0p
|
|
|
|
|
|
|
|
|
Diluted
earnings/(loss) per share
|
(1.4)p
|
|
35.6p
|
|
52.2p
|
|
111.4p
|
|
|
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
Q3
2024
£m
|
|
Q3
2023
£m
|
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
|
|
|
|
|
|
|
Total
profit for the period
|
65
|
|
1,534
|
|
2,450
|
|
4,910
|
|
|
|
|
|
|
|
|
Items
that may be reclassified subsequently to income
statement:
|
|
|
|
|
|
|
|
Exchange movements
on overseas net assets and net
investment hedges
|
164
|
|
(94)
|
|
(47)
|
|
(87)
|
Reclassification of
exchange movements on liquidation or
disposal of overseas subsidiaries and associates
|
(57)
|
|
(7)
|
|
(56)
|
|
(20)
|
Fair
value movements on cash flow hedges
|
(1)
|
|
–
|
|
(1)
|
|
1
|
Cost of
hedging
|
(5)
|
|
–
|
|
(5)
|
|
–
|
Deferred tax on
fair value movements on cash flow hedges
|
(1)
|
|
–
|
|
(1)
|
|
(1)
|
Reclassification of
cash flow hedges to income statement
|
2
|
|
1
|
|
4
|
|
4
|
|
|
|
|
|
|
|
|
|
102
|
|
(100)
|
|
(106)
|
|
(103)
|
|
|
|
|
|
|
|
|
Items
that will not be reclassified to income statement:
|
|
|
|
|
|
|
|
Exchange movements
on overseas net assets of
non-controlling interests
|
(24)
|
|
5
|
|
(17)
|
|
(17)
|
Fair
value movements on equity investments
|
(27)
|
|
(242)
|
|
(108)
|
|
(359)
|
Tax on
fair value movements on equity investments
|
3
|
|
18
|
|
6
|
|
35
|
Fair
value movements on cash flow hedges
|
3
|
|
–
|
|
2
|
|
(34)
|
Remeasurement
gains/(losses) on defined benefit plans
|
192
|
|
(266)
|
|
373
|
|
(216)
|
Tax on
remeasurement losses/(gains) on defined benefit
plans
|
(45)
|
|
63
|
|
(87)
|
|
55
|
|
|
|
|
|
|
|
|
|
102
|
|
(422)
|
|
169
|
|
(536)
|
|
|
|
|
|
|
|
|
Other
comprehensive income/(expense) for the period
|
204
|
|
(522)
|
|
63
|
|
(639)
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
269
|
|
1,012
|
|
2,513
|
|
4,271
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
|
|
|
Shareholders
|
170
|
|
937
|
|
2,241
|
|
3,956
|
Non-controlling interests
|
99
|
|
75
|
|
272
|
|
315
|
|
|
|
|
|
|
|
|
|
269
|
|
1,012
|
|
2,513
|
|
4,271
|
|
Balance sheet
|
|
|
|
|
|
30
September 2024
£m
|
|
31
December 2023
£m
|
ASSETS
|
|
|
|
Non-current
assets
|
|
|
|
Property, plant and
equipment
|
8,885
|
|
9,020
|
Right
of use assets
|
840
|
|
937
|
Goodwill
|
6,680
|
|
6,811
|
Other
intangible assets
|
15,010
|
|
14,768
|
Investments in
associates and joint ventures
|
81
|
|
55
|
Other
investments
|
1,023
|
|
1,137
|
Deferred tax
assets
|
6,288
|
|
6,049
|
Derivative
instruments
|
4
|
|
–
|
Other
non-current assets
|
1,940
|
|
1,584
|
|
|
|
|
Total
non-current assets
|
40,751
|
|
40,361
|
|
|
|
|
Current
assets
|
|
|
|
Inventories
|
5,918
|
|
5,498
|
Current
tax recoverable
|
484
|
|
373
|
Trade
and other receivables
|
7,383
|
|
7,385
|
Derivative
financial instruments
|
241
|
|
130
|
Current
equity investments
|
–
|
|
2,204
|
Liquid
investments
|
20
|
|
42
|
Cash
and cash equivalents
|
3,192
|
|
2,936
|
Assets
held for sale
|
60
|
|
76
|
|
|
|
|
Total
current assets
|
17,298
|
|
18,644
|
|
|
|
|
TOTAL
ASSETS
|
58,049
|
|
59,005
|
|
|
|
|
LIABILITIES
|
|
|
|
Current
liabilities
|
|
|
|
Short-term
borrowings
|
(2,815)
|
|
(2,813)
|
Contingent
consideration liabilities
|
(1,105)
|
|
(1,053)
|
Trade
and other payables
|
(14,375)
|
|
(15,844)
|
Derivative
financial instruments
|
(146)
|
|
(114)
|
Current
tax payable
|
(568)
|
|
(500)
|
Short-term
provisions
|
(2,450)
|
|
(744)
|
|
|
|
|
Total
current liabilities
|
(21,459)
|
|
(21,068)
|
|
|
|
|
Non-current
liabilities
|
|
|
|
Long-term
borrowings
|
(13,244)
|
|
(15,205)
|
Corporation tax
payable
|
(19)
|
|
(75)
|
Deferred tax
liabilities
|
(294)
|
|
(311)
|
Pensions and other
post-employment benefits
|
(2,028)
|
|
(2,340)
|
Other
provisions
|
(492)
|
|
(495)
|
Contingent
consideration liabilities
|
(6,020)
|
|
(5,609)
|
Other
non-current liabilities
|
(1,040)
|
|
(1,107)
|
|
|
|
|
Total
non-current liabilities
|
(23,137)
|
|
(25,142)
|
|
|
|
|
TOTAL
LIABILITIES
|
(44,596)
|
|
(46,210)
|
|
|
|
|
NET
ASSETS
|
13,453
|
|
12,795
|
|
|
|
|
EQUITY
|
|
|
|
Share
capital
|
1,348
|
|
1,348
|
Share
premium account
|
3,473
|
|
3,451
|
Retained
earnings
|
8,187
|
|
7,239
|
Other
reserves
|
1,000
|
|
1,309
|
|
|
|
|
Shareholders’
equity
|
14,008
|
|
13,347
|
|
|
|
|
Non-controlling
interests
|
(555)
|
|
(552)
|
|
|
|
|
TOTAL
EQUITY
|
13,453
|
|
12,795
|
Statement of changes in equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2024
|
1,348
|
|
3,451
|
|
7,239
|
|
1,309
|
|
13,347
|
|
(552)
|
|
12,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
2,161
|
|
|
|
2,161
|
|
289
|
|
2,450
|
Other comprehensive
income/(expense) for the period
|
|
|
|
|
146
|
|
(66)
|
|
80
|
|
(17)
|
|
63
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for the period
|
|
|
|
|
2,307
|
|
(66)
|
|
2,241
|
|
272
|
|
2,513
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions to
non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(288)
|
|
(288)
|
Dividends to
shareholders
|
|
|
|
|
(1,832)
|
|
|
|
(1,832)
|
|
|
|
(1,832)
|
Realised after tax
losses on disposal
or liquidation of equity investments
|
|
|
|
|
15
|
|
(15)
|
|
|
|
|
|
–
|
Share
of associates and joint ventures
realised profit/(loss) on disposal of
equity investments
|
|
|
|
|
52
|
|
(52)
|
|
|
|
|
|
–
|
Shares
issued
|
|
|
20
|
|
|
|
|
|
20
|
|
|
|
20
|
Write-down on
shares held by ESOP Trusts
|
|
|
|
|
(283)
|
|
283
|
|
|
|
|
|
–
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
457
|
|
(459)
|
|
|
|
|
|
–
|
Share-based
incentive plans
|
|
|
|
|
232
|
|
|
|
232
|
|
|
|
232
|
Contributions from
non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
9
|
|
9
|
Changes
to non-controlling interests
|
|
|
|
|
|
|
|
|
–
|
|
4
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At
30 September 2024
|
1,348
|
|
3,473
|
|
8,187
|
|
1,000
|
|
14,008
|
|
(555)
|
|
13,453
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2023
|
1,347
|
|
3,440
|
|
4,363
|
|
1,448
|
|
10,598
|
|
(502)
|
|
10,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
4,578
|
|
–
|
|
4,578
|
|
332
|
|
4,910
|
Other comprehensive
income/(expense) for the period
|
|
|
|
|
(279)
|
|
(343)
|
|
(622)
|
|
(17)
|
|
(639)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for the period
|
|
|
|
|
4,299
|
|
(343)
|
|
3,956
|
|
315
|
|
4,271
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions to
non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(334)
|
|
(334)
|
Contributions from
non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
Dividends to
shareholders
|
|
|
|
|
(1,679)
|
|
|
|
(1,679)
|
|
|
|
(1,679)
|
Realised after tax
losses on disposal or
liquidation of equity investments
|
|
|
|
|
(33)
|
|
33
|
|
|
|
|
|
–
|
Share
of associates and joint ventures
realised profit/(loss) on disposal of
equity investments
|
|
|
|
|
2
|
|
(2)
|
|
|
|
|
|
–
|
Share
issued
|
1
|
|
8
|
|
|
|
|
|
9
|
|
|
|
9
|
Write-down of
shares held by ESOP Trusts
|
|
|
|
|
(153)
|
|
153
|
|
|
|
|
|
–
|
Shares
acquired by ESOP Trusts
|
|
|
2
|
|
1
|
|
(3)
|
|
|
|
|
|
–
|
Share-based
incentive plans
|
|
|
|
|
217
|
|
|
|
217
|
|
|
|
217
|
Hedging
gain/(loss) after taxation
transferred to non-financial assets
|
|
|
|
|
|
|
32
|
|
32
|
|
|
|
32
|
At 30
September 2023
|
1,348
|
|
3,450
|
|
7,017
|
|
1,318
|
|
13,133
|
|
(514)
|
|
12,619
|
Cash flow statement nine months ended 30 September
2024
|
|
9
months 2024
£m
|
|
9
months 2023
£m
|
Profit
after tax
|
2,450
|
|
4,910
|
Tax on
profits
|
464
|
|
775
|
Share
of after tax loss/(profit) of associates and joint
ventures
|
3
|
|
4
|
(Profit)/loss on
disposal of interest in associates and joint ventures
|
–
|
|
(1)
|
Net
finance expense
|
408
|
|
484
|
Depreciation,
amortisation and other adjusting items
|
2,139
|
|
1,671
|
(Increase)/decrease
in working capital
|
(1,669)
|
|
(2,669)
|
Contingent
consideration paid
|
(924)
|
|
(853)
|
Increase/(decrease)
in other net liabilities (excluding contingent consideration
paid)
|
2,404
|
|
94
|
Cash
generated from operations
|
5,275
|
|
4,415
|
Taxation
paid
|
(1,050)
|
|
(843)
|
Total
net cash inflow/(outflow) from operating activities
|
4,225
|
|
3,572
|
|
|
|
|
Cash
flow from investing activities
|
|
|
|
Purchase of
property, plant and equipment
|
(855)
|
|
(828)
|
Proceeds from sale
of property, plant and equipment
|
4
|
|
21
|
Purchase of
intangible assets
|
(992)
|
|
(733)
|
Proceeds from sale
of intangible assets
|
126
|
|
12
|
Purchase of equity
investments
|
(76)
|
|
(92)
|
Proceeds from sale
of equity investments
|
2,354
|
|
834
|
Purchase of
businesses, net of cash acquired
|
(748)
|
|
(1,459)
|
Investment in joint
ventures and associates
|
(42)
|
|
–
|
Contingent
consideration paid
|
(11)
|
|
(7)
|
Disposal of
businesses
|
(13)
|
|
56
|
Interest
received
|
91
|
|
83
|
(Increase)/decrease
in liquid investments
|
21
|
|
47
|
Dividends from
joint ventures and associates
|
15
|
|
1
|
Dividend and
distributions from investments
|
16
|
|
201
|
Proceeds from
disposal of associates and Joint ventures
|
–
|
|
1
|
Total
net cash inflow/(outflow) from investing activities
|
(110)
|
|
(1,863)
|
|
|
|
|
Cash
flow from financing activities
|
|
|
|
Issue
of share capital
|
20
|
|
9
|
Repayment of
long-term loans
|
–
|
|
(144)
|
Issue
of long-term notes
|
–
|
|
238
|
Repayment of
short-term loans
|
(787)
|
|
(1,088)
|
Net
increase/(repayment) of other short-term loans
|
(623)
|
|
1,394
|
Repayment of lease
liabilities
|
(170)
|
|
(148)
|
Interest
paid
|
(385)
|
|
(480)
|
Dividends paid to
shareholders
|
(1,832)
|
|
(1,679)
|
Distribution to
non-controlling interests
|
(288)
|
|
(334)
|
Contributions from
non-controlling interests
|
9
|
|
7
|
Other
financing items
|
172
|
|
176
|
Total
net cash inflow/(outflow) from financing activities
|
(3,884)
|
|
(2,049)
|
Increase/(decrease)
in cash and bank overdrafts in the period
|
231
|
|
(340)
|
Cash
and bank overdrafts at beginning of the period
|
2,858
|
|
3,425
|
Exchange
adjustments
|
(61)
|
|
(65)
|
Increase/(decrease)
in cash and bank overdrafts
|
231
|
|
(340)
|
Cash
and bank overdrafts at end of the period
|
3,028
|
|
3,020
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
Cash
and cash equivalents
|
3,192
|
|
3,177
|
Overdrafts
|
(164)
|
|
(157)
|
|
3,028
|
|
3,020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Shingles
|
739
|
|
(10)
|
|
(7)
|
|
307
|
|
(26)
|
|
(23)
|
|
194
|
|
(15)
|
|
(13)
|
|
238
|
|
29
|
|
35
|
Shingrix
|
739
|
|
(10)
|
|
(7)
|
|
307
|
|
(26)
|
|
(23)
|
|
194
|
|
(15)
|
|
(13)
|
|
238
|
|
29
|
|
35
|
Meningitis
|
520
|
|
18
|
|
22
|
|
316
|
|
16
|
|
20
|
|
122
|
|
12
|
|
15
|
|
82
|
|
37
|
|
47
|
Bexsero
|
334
|
|
26
|
|
30
|
|
168
|
|
27
|
|
31
|
|
120
|
|
15
|
|
17
|
|
46
|
|
53
|
|
73
|
Menveo
|
173
|
|
3
|
|
7
|
|
148
|
|
6
|
|
10
|
|
1
|
|
(67)
|
|
(33)
|
|
24
|
|
(4)
|
|
(8)
|
Other
|
13
|
|
86
|
|
100
|
|
–
|
|
–
|
|
–
|
|
1
|
|
(50)
|
|
(50)
|
|
12
|
|
>100
|
|
>100
|
RSV
|
188
|
|
(73)
|
|
(72)
|
|
177
|
|
(75)
|
|
(74)
|
|
5
|
|
>100
|
|
>100
|
|
6
|
|
(14)
|
|
(29)
|
Arexvy
|
188
|
|
(73)
|
|
(72)
|
|
177
|
|
(75)
|
|
(74)
|
|
5
|
|
>100
|
|
>100
|
|
6
|
|
(14)
|
|
(29)
|
Influenza
|
283
|
|
(24)
|
|
(22)
|
|
243
|
|
(23)
|
|
(21)
|
|
15
|
|
(29)
|
|
(29)
|
|
25
|
|
(31)
|
|
(22)
|
Fluarix, FluLaval
|
283
|
|
(24)
|
|
(22)
|
|
243
|
|
(23)
|
|
(21)
|
|
15
|
|
(29)
|
|
(29)
|
|
25
|
|
(31)
|
|
(22)
|
Established
Vaccines
|
920
|
|
6
|
|
10
|
|
415
|
|
21
|
|
26
|
|
186
|
|
9
|
|
12
|
|
319
|
|
(10)
|
|
(6)
|
Infanrix, Pediarix
|
151
|
|
4
|
|
8
|
|
95
|
|
16
|
|
21
|
|
27
|
|
4
|
|
8
|
|
29
|
|
(22)
|
|
(19)
|
Boostrix
|
211
|
|
25
|
|
30
|
|
141
|
|
15
|
|
19
|
|
35
|
|
21
|
|
21
|
|
35
|
|
>100
|
|
>100
|
Hepatitis
|
183
|
|
17
|
|
22
|
|
112
|
|
18
|
|
22
|
|
46
|
|
15
|
|
20
|
|
25
|
|
14
|
|
27
|
Rotarix
|
153
|
|
6
|
|
10
|
|
52
|
|
53
|
|
59
|
|
29
|
|
4
|
|
7
|
|
72
|
|
(12)
|
|
(10)
|
Synflorix
|
50
|
|
(44)
|
|
(42)
|
|
–
|
|
–
|
|
–
|
|
4
|
|
(50)
|
|
(50)
|
|
46
|
|
(43)
|
|
(41)
|
Priorix, Priorix Tetra,
Varilrix
|
83
|
|
1
|
|
4
|
|
12
|
|
>100
|
|
>100
|
|
32
|
|
(9)
|
|
(6)
|
|
39
|
|
(9)
|
|
(5)
|
Cervarix
|
18
|
|
(42)
|
|
(42)
|
|
–
|
|
–
|
|
–
|
|
4
|
|
100
|
|
100
|
|
14
|
|
(52)
|
|
(52)
|
Other
|
71
|
|
39
|
|
41
|
|
3
|
|
(40)
|
|
–
|
|
9
|
|
>100
|
|
>100
|
|
59
|
|
34
|
|
34
|
Vaccines
excluding
COVID-19 solutions
|
2,650
|
|
(18)
|
|
(15)
|
|
1,458
|
|
(29)
|
|
(26)
|
|
522
|
|
(1)
|
|
1
|
|
670
|
|
4
|
|
10
|
Pandemic
vaccines
|
–
|
|
(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
>(100)
|
Pandemic
adjuvant
|
–
|
|
(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
>(100)
|
Vaccines
|
2,650
|
|
(18)
|
|
(15)
|
|
1,458
|
|
(29)
|
|
(26)
|
|
522
|
|
(1)
|
|
1
|
|
670
|
|
4
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Shingles
|
2,516
|
|
(1)
|
|
2
|
|
1,078
|
|
(23)
|
|
(20)
|
|
667
|
|
(2)
|
|
(1)
|
|
771
|
|
68
|
|
76
|
Shingrix
|
2,516
|
|
(1)
|
|
2
|
|
1,078
|
|
(23)
|
|
(20)
|
|
667
|
|
(2)
|
|
(1)
|
|
771
|
|
68
|
|
76
|
Meningitis
|
1,142
|
|
16
|
|
20
|
|
580
|
|
14
|
|
17
|
|
339
|
|
3
|
|
5
|
|
223
|
|
52
|
|
60
|
Bexsero
|
783
|
|
15
|
|
19
|
|
325
|
|
18
|
|
22
|
|
331
|
|
5
|
|
7
|
|
127
|
|
46
|
|
56
|
Menveo
|
337
|
|
15
|
|
19
|
|
255
|
|
8
|
|
11
|
|
5
|
|
(44)
|
|
(33)
|
|
77
|
|
60
|
|
65
|
Other
|
22
|
|
37
|
|
44
|
|
–
|
|
–
|
|
–
|
|
3
|
|
(25)
|
|
(25)
|
|
19
|
|
58
|
|
67
|
RSV
|
432
|
|
(39)
|
|
(37)
|
|
387
|
|
(45)
|
|
(43)
|
|
6
|
|
>100
|
|
>100
|
|
39
|
|
>100
|
|
>100
|
Arexvy
|
432
|
|
(39)
|
|
(37)
|
|
387
|
|
(45)
|
|
(43)
|
|
6
|
|
>100
|
|
>100
|
|
39
|
|
>100
|
|
>100
|
Influenza
|
303
|
|
(26)
|
|
(23)
|
|
244
|
|
(23)
|
|
(21)
|
|
14
|
|
(33)
|
|
(33)
|
|
45
|
|
(36)
|
|
(31)
|
Fluarix, FluLaval
|
303
|
|
(26)
|
|
(23)
|
|
244
|
|
(23)
|
|
(21)
|
|
14
|
|
(33)
|
|
(33)
|
|
45
|
|
(36)
|
|
(31)
|
Established
Vaccines
|
2,533
|
|
2
|
|
5
|
|
1,012
|
|
1
|
|
4
|
|
542
|
|
(2)
|
|
–
|
|
979
|
|
4
|
|
9
|
Infanrix, Pediarix
|
390
|
|
(4)
|
|
(1)
|
|
206
|
|
(8)
|
|
(5)
|
|
87
|
|
10
|
|
13
|
|
97
|
|
(7)
|
|
(2)
|
Boostrix
|
532
|
|
13
|
|
16
|
|
337
|
|
7
|
|
10
|
|
104
|
|
13
|
|
15
|
|
91
|
|
42
|
|
50
|
Hepatitis
|
521
|
|
7
|
|
11
|
|
295
|
|
7
|
|
10
|
|
143
|
|
8
|
|
11
|
|
83
|
|
8
|
|
14
|
Rotarix
|
431
|
|
(8)
|
|
(4)
|
|
137
|
|
(14)
|
|
(11)
|
|
88
|
|
(1)
|
|
1
|
|
206
|
|
(6)
|
|
–
|
Synflorix
|
157
|
|
(31)
|
|
(28)
|
|
–
|
|
–
|
|
–
|
|
7
|
|
(74)
|
|
(74)
|
|
150
|
|
(25)
|
|
(22)
|
Priorix, Priorix Tetra,
Varilrix
|
240
|
|
27
|
|
31
|
|
26
|
|
>100
|
|
>100
|
|
93
|
|
(5)
|
|
(3)
|
|
121
|
|
51
|
|
58
|
Cervarix
|
66
|
|
(40)
|
|
(38)
|
|
–
|
|
–
|
|
–
|
|
11
|
|
(63)
|
|
(63)
|
|
55
|
|
(31)
|
|
(29)
|
Other
|
196
|
|
41
|
|
44
|
|
11
|
|
(42)
|
|
(37)
|
|
9
|
|
80
|
|
60
|
|
176
|
|
53
|
|
57
|
Vaccines
excluding
COVID-19 solutions
|
6,926
|
|
(3)
|
|
–
|
|
3,301
|
|
(16)
|
|
(13)
|
|
1,568
|
|
(1)
|
|
1
|
|
2,057
|
|
27
|
|
33
|
Pandemic
vaccines
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
(100)
|
|
(100)
|
Pandemic
adjuvant
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
–
|
|
–
|
|
–
|
|
(100)
|
|
(100)
|
|
–
|
|
(100)
|
|
(100)
|
Vaccines
|
6,926
|
|
(5)
|
|
(2)
|
|
3,301
|
|
(16)
|
|
(13)
|
|
1,568
|
|
(8)
|
|
(7)
|
|
2,057
|
|
25
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
HIV
|
1,750
|
|
8
|
|
12
|
|
1,172
|
|
8
|
|
12
|
|
363
|
|
5
|
|
7
|
|
215
|
|
13
|
|
18
|
Dolutegravir
products
|
1,388
|
|
2
|
|
6
|
|
867
|
|
—
|
|
4
|
|
318
|
|
2
|
|
4
|
|
203
|
|
12
|
|
15
|
Tivicay
|
335
|
|
(1)
|
|
2
|
|
187
|
|
(3)
|
|
1
|
|
60
|
|
(6)
|
|
(5)
|
|
88
|
|
5
|
|
8
|
Triumeq
|
323
|
|
(13)
|
|
(10)
|
|
230
|
|
(13)
|
|
(9)
|
|
52
|
|
(20)
|
|
(20)
|
|
41
|
|
(9)
|
|
(2)
|
Juluca
|
163
|
|
(5)
|
|
(1)
|
|
128
|
|
(4)
|
|
1
|
|
31
|
|
(9)
|
|
(9)
|
|
4
|
|
33
|
|
–
|
Dovato
|
567
|
|
19
|
|
23
|
|
322
|
|
16
|
|
21
|
|
175
|
|
17
|
|
20
|
|
70
|
|
40
|
|
44
|
Rukobia
|
39
|
|
30
|
|
37
|
|
37
|
|
32
|
|
36
|
|
2
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
Cabenuva
|
245
|
|
35
|
|
40
|
|
200
|
|
32
|
|
38
|
|
39
|
|
50
|
|
54
|
|
6
|
|
20
|
|
20
|
Apretude
|
69
|
|
86
|
|
95
|
|
66
|
|
78
|
|
86
|
|
–
|
|
–
|
|
–
|
|
3
|
|
–
|
|
–
|
Other
|
9
|
|
(31)
|
|
(31)
|
|
2
|
|
(60)
|
|
>(100)
|
|
4
|
|
(20)
|
|
–
|
|
3
|
|
–
|
|
33
|
Respiratory/Immunology
and Other
|
843
|
|
10
|
|
14
|
|
555
|
|
5
|
|
9
|
|
139
|
|
17
|
|
20
|
|
149
|
|
22
|
|
29
|
Nucala
|
444
|
|
8
|
|
12
|
|
235
|
|
(2)
|
|
2
|
|
114
|
|
18
|
|
19
|
|
95
|
|
27
|
|
36
|
Benlysta
|
389
|
|
11
|
|
16
|
|
318
|
|
11
|
|
15
|
|
28
|
|
12
|
|
16
|
|
43
|
|
16
|
|
22
|
Other
|
10
|
|
43
|
|
43
|
|
2
|
|
>100
|
|
>100
|
|
(3)
|
|
–
|
|
67
|
|
11
|
|
10
|
|
—
|
Oncology
|
373
|
|
86
|
|
94
|
|
264
|
|
>100
|
|
>100
|
|
88
|
|
22
|
|
24
|
|
21
|
|
24
|
|
41
|
Zejula
|
144
|
|
3
|
|
6
|
|
72
|
|
1
|
|
4
|
|
55
|
|
2
|
|
4
|
|
17
|
|
13
|
|
27
|
Blenrep
|
3
|
|
(70)
|
|
(80)
|
|
–
|
|
–
|
|
–
|
|
3
|
|
(70)
|
|
(80)
|
|
–
|
|
–
|
|
–
|
Jemperli
|
130
|
|
>100
|
|
>100
|
|
106
|
|
>100
|
|
>100
|
|
21
|
|
>100
|
|
>100
|
|
3
|
|
>100
|
|
>100
|
Ojjaara/Omjjara
|
98
|
|
>100
|
|
>100
|
|
86
|
|
>100
|
|
>100
|
|
11
|
|
–
|
|
–
|
|
1
|
|
–
|
|
–
|
Other
|
(2)
|
|
>(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
(2)
|
|
>(100)
|
|
>(100)
|
|
–
|
|
>(100)
|
|
–
|
Specialty
Medicines
excluding COVID-19
solutions
|
2,966
|
|
14
|
|
19
|
|
1,991
|
|
15
|
|
20
|
|
590
|
|
10
|
|
12
|
|
385
|
|
17
|
|
23
|
Pandemic
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
Xevudy
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
|
–
|
Specialty
Medicines
|
2,966
|
|
14
|
|
19
|
|
1,991
|
|
15
|
|
20
|
|
590
|
|
10
|
|
12
|
|
385
|
|
17
|
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
HIV
|
5,120
|
|
10
|
|
13
|
|
3,394
|
|
11
|
|
14
|
|
1,109
|
|
6
|
|
8
|
|
617
|
|
10
|
|
16
|
Dolutegravir
products
|
4,083
|
|
3
|
|
6
|
|
2,520
|
|
2
|
|
5
|
|
981
|
|
3
|
|
4
|
|
582
|
|
9
|
|
14
|
Tivicay
|
1,007
|
|
(3)
|
|
–
|
|
566
|
|
(4)
|
|
(1)
|
|
190
|
|
(5)
|
|
(3)
|
|
251
|
|
–
|
|
5
|
Triumeq
|
979
|
|
(14)
|
|
(11)
|
|
682
|
|
(13)
|
|
(10)
|
|
172
|
|
(20)
|
|
(19)
|
|
125
|
|
(13)
|
|
(8)
|
Juluca
|
496
|
|
2
|
|
6
|
|
391
|
|
5
|
|
9
|
|
95
|
|
(8)
|
|
(6)
|
|
10
|
|
–
|
|
–
|
Dovato
|
1,601
|
|
23
|
|
26
|
|
881
|
|
21
|
|
24
|
|
524
|
|
19
|
|
21
|
|
196
|
|
50
|
|
56
|
Rukobia
|
110
|
|
34
|
|
39
|
|
104
|
|
37
|
|
41
|
|
6
|
|
20
|
|
20
|
|
–
|
|
>(100)
|
|
–
|
Cabenuva
|
703
|
|
45
|
|
49
|
|
575
|
|
43
|
|
48
|
|
110
|
|
55
|
|
58
|
|
18
|
|
50
|
|
58
|
Apretude
|
195
|
|
>100
|
|
>100
|
|
189
|
|
95
|
|
>100
|
|
–
|
|
–
|
|
–
|
|
6
|
|
–
|
|
–
|
Other
|
29
|
|
(34)
|
|
(32)
|
|
6
|
|
(57)
|
|
(64)
|
|
12
|
|
(25)
|
|
(19)
|
|
11
|
|
(21)
|
|
(14)
|
Respiratory/Immunology
and Other
|
2,389
|
|
10
|
|
15
|
|
1,570
|
|
6
|
|
10
|
|
409
|
|
19
|
|
22
|
|
410
|
|
19
|
|
29
|
Nucala
|
1,300
|
|
10
|
|
14
|
|
702
|
|
2
|
|
6
|
|
335
|
|
19
|
|
21
|
|
263
|
|
21
|
|
32
|
Benlysta
|
1,067
|
|
11
|
|
15
|
|
866
|
|
10
|
|
13
|
|
85
|
|
16
|
|
19
|
|
116
|
|
17
|
|
25
|
Other
|
22
|
|
22
|
|
33
|
|
2
|
|
>100
|
|
–
|
|
(11)
|
|
–
|
|
9
|
|
31
|
|
11
|
|
18
|
Oncology
|
1,002
|
|
>100
|
|
>100
|
|
701
|
|
>100
|
|
>100
|
|
249
|
|
14
|
|
16
|
|
52
|
|
49
|
|
57
|
Zejula
|
450
|
|
21
|
|
25
|
|
232
|
|
35
|
|
39
|
|
174
|
|
5
|
|
7
|
|
44
|
|
33
|
|
39
|
Blenrep
|
1
|
|
(97)
|
|
(97)
|
|
(3)
|
|
(50)
|
|
(50)
|
|
4
|
|
(88)
|
|
(88)
|
|
–
|
|
–
|
|
–
|
Jemperli
|
318
|
|
>100
|
|
>100
|
|
259
|
|
>100
|
|
>100
|
|
52
|
|
>100
|
|
>100
|
|
7
|
|
>100
|
|
>100
|
Ojjaara/Omjjara
|
235
|
|
>100
|
|
>100
|
|
213
|
|
>100
|
|
>100
|
|
21
|
|
–
|
|
–
|
|
1
|
|
–
|
|
–
|
Other
|
(2)
|
|
>(100)
|
|
>(100)
|
|
–
|
|
–
|
|
–
|
|
(2)
|
|
>(100)
|
|
>(100)
|
|
–
|
|
>(100)
|
|
–
|
Specialty
Medicines
excluding COVID-19
solutions
|
8,511
|
|
16
|
|
20
|
|
5,665
|
|
19
|
|
22
|
|
1,767
|
|
10
|
|
12
|
|
1,079
|
|
15
|
|
22
|
Pandemic
|
1
|
|
(97)
|
|
(97)
|
|
–
|
|
100
|
|
100
|
|
–
|
|
>(100)
|
|
>(100)
|
|
1
|
|
(97)
|
|
(97)
|
Xevudy
|
1
|
|
(97)
|
|
(97)
|
|
–
|
|
100
|
|
100
|
|
–
|
|
>(100)
|
|
>(100)
|
|
1
|
|
(97)
|
|
(97)
|
Specialty
Medicines
|
8,512
|
|
16
|
|
20
|
|
5,665
|
|
19
|
|
23
|
|
1,767
|
|
10
|
|
12
|
|
1,080
|
|
11
|
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Respiratory
|
1,617
|
|
6
|
|
11
|
|
820
|
|
10
|
|
15
|
|
338
|
|
7
|
|
9
|
|
459
|
|
1
|
|
7
|
Anoro Ellipta
|
146
|
|
3
|
|
6
|
|
67
|
|
(6)
|
|
(1)
|
|
56
|
|
17
|
|
19
|
|
23
|
|
–
|
|
4
|
Flixotide/Flovent
|
113
|
|
15
|
|
20
|
|
73
|
|
11
|
|
15
|
|
15
|
|
25
|
|
33
|
|
25
|
|
25
|
|
30
|
Relvar/Breo Ellipta
|
241
|
|
1
|
|
5
|
|
86
|
|
–
|
|
3
|
|
85
|
|
5
|
|
7
|
|
70
|
|
(3)
|
|
4
|
Seretide/Advair
|
218
|
|
8
|
|
13
|
|
61
|
|
>100
|
|
>100
|
|
50
|
|
(9)
|
|
(7)
|
|
107
|
|
(17)
|
|
(12)
|
Trelegy Ellipta
|
600
|
|
12
|
|
16
|
|
420
|
|
8
|
|
13
|
|
79
|
|
14
|
|
17
|
|
101
|
|
26
|
|
31
|
Ventolin
|
176
|
|
1
|
|
5
|
|
90
|
|
(2)
|
|
1
|
|
25
|
|
4
|
|
4
|
|
61
|
|
3
|
|
12
|
Other
Respiratory
|
123
|
|
(3)
|
|
2
|
|
23
|
|
(12)
|
|
(4)
|
|
28
|
|
–
|
|
–
|
|
72
|
|
(1)
|
|
4
|
Other
General Medicines
|
779
|
|
(5)
|
|
–
|
|
52
|
|
30
|
|
37
|
|
168
|
|
(5)
|
|
(4)
|
|
559
|
|
(7)
|
|
(1)
|
Augmentin
|
146
|
|
(8)
|
|
(1)
|
|
–
|
|
–
|
|
–
|
|
43
|
|
5
|
|
7
|
|
103
|
|
(12)
|
|
(4)
|
Lamictal
|
94
|
|
13
|
|
18
|
|
37
|
|
61
|
|
70
|
|
27
|
|
(4)
|
|
(4)
|
|
30
|
|
(6)
|
|
–
|
Other
"Other General Medicines"
|
539
|
|
(6)
|
|
(2)
|
|
15
|
|
(12)
|
|
(6)
|
|
98
|
|
(9)
|
|
(8)
|
|
426
|
|
(6)
|
|
–
|
General
Medicines
|
2,396
|
|
3
|
|
7
|
|
872
|
|
11
|
|
16
|
|
506
|
|
2
|
|
4
|
|
1,018
|
|
(4)
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Respiratory
|
5,407
|
|
6
|
|
11
|
|
2,912
|
|
15
|
|
19
|
|
1,055
|
|
1
|
|
3
|
|
1,440
|
|
(5)
|
|
2
|
Anoro Ellipta
|
425
|
|
6
|
|
9
|
|
192
|
|
1
|
|
4
|
|
164
|
|
15
|
|
18
|
|
69
|
|
–
|
|
6
|
Flixotide/Flovent
|
384
|
|
9
|
|
13
|
|
259
|
|
15
|
|
19
|
|
51
|
|
2
|
|
4
|
|
74
|
|
(3)
|
|
3
|
Relvar/Breo Ellipta
|
792
|
|
(1)
|
|
3
|
|
300
|
|
(2)
|
|
1
|
|
275
|
|
1
|
|
4
|
|
217
|
|
(3)
|
|
5
|
Seretide/Advair
|
798
|
|
(8)
|
|
(4)
|
|
273
|
|
4
|
|
7
|
|
166
|
|
(13)
|
|
(12)
|
|
359
|
|
(12)
|
|
(7)
|
Trelegy Ellipta
|
2,033
|
|
26
|
|
31
|
|
1,512
|
|
29
|
|
33
|
|
230
|
|
13
|
|
15
|
|
291
|
|
24
|
|
33
|
Ventolin
|
532
|
|
(3)
|
|
–
|
|
276
|
|
(4)
|
|
(1)
|
|
76
|
|
6
|
|
7
|
|
180
|
|
(6)
|
|
(1)
|
Other
Respiratory
|
443
|
|
(11)
|
|
(7)
|
|
100
|
|
25
|
|
29
|
|
93
|
|
(16)
|
|
(15)
|
|
250
|
|
(19)
|
|
(13)
|
Other
General Medicines
|
2,414
|
|
(6)
|
|
(1)
|
|
179
|
|
(16)
|
|
(13)
|
|
521
|
|
(4)
|
|
(3)
|
|
1,714
|
|
(5)
|
|
1
|
Augmentin
|
474
|
|
1
|
|
6
|
|
–
|
|
–
|
|
–
|
|
138
|
|
1
|
|
2
|
|
336
|
|
1
|
|
8
|
Lamictal
|
304
|
|
(7)
|
|
(3)
|
|
123
|
|
(15)
|
|
(12)
|
|
81
|
|
(2)
|
|
(1)
|
|
100
|
|
1
|
|
8
|
Other
"Other General Medicines"
|
1,636
|
|
(8)
|
|
(2)
|
|
56
|
|
(19)
|
|
(14)
|
|
302
|
|
(7)
|
|
(5)
|
|
1,278
|
|
(7)
|
|
(1)
|
General
Medicines
|
7,821
|
|
2
|
|
7
|
|
3,091
|
|
13
|
|
16
|
|
1,576
|
|
(1)
|
|
1
|
|
3,154
|
|
(5)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Three
months ended 30 September 2024
|
8,012
|
|
(2)
|
|
2
|
|
4,321
|
|
(5)
|
|
(1)
|
|
1,618
|
|
4
|
|
6
|
|
2,073
|
|
2
|
|
8
|
Nine
months ended 30 September 2024
|
23,259
|
|
4
|
|
8
|
|
12,057
|
|
5
|
|
9
|
|
4,911
|
|
–
|
|
2
|
|
6,291
|
|
6
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
Three months ended 30 September 2024
|
8,012
|
|
(2)
|
|
2
|
|
4,321
|
|
(5)
|
|
(1)
|
|
1,618
|
|
4
|
|
6
|
|
2,073
|
|
2
|
|
8
|
Nine months ended 30 September 2024
|
23,258
|
|
5
|
|
9
|
|
12,057
|
|
5
|
|
9
|
|
4,911
|
|
3
|
|
5
|
|
6,290
|
|
7
|
|
13
|
|
|
|
|
|
|
|
|
Turnover
by segment
|
|||||||
|
Q3
2024
£m
|
|
Q3
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
8,012
|
|
8,147
|
|
(2)
|
|
2
|
|
|
|
|
|
|
|
|
Operating
profit by segment
|
|||||||
|
Q3
2024
£m
|
|
Q3
2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
4,195
|
|
4,188
|
|
–
|
|
5
|
Research and
Development
|
(1,334)
|
|
(1,371)
|
|
(3)
|
|
–
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,861
|
|
2,817
|
|
2
|
|
7
|
Corporate and other
unallocated costs
|
(100)
|
|
(45)
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
2,761
|
|
2,772
|
|
–
|
|
5
|
Adjusting
items
|
(2,572)
|
|
(823)
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
189
|
|
1,949
|
|
(90)
|
|
(86)
|
|
|
|
|
|
|
|
|
Finance
income
|
32
|
|
24
|
|
|
|
|
Finance
costs
|
(156)
|
|
(182)
|
|
|
|
|
Share
of after tax profit/(loss) of associates and
joint ventures
|
(1)
|
|
–
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
64
|
|
1,791
|
|
(96)
|
|
(92)
|
|
|
|
|
|
|
|
|
Turnover
by segment
|
|||||||
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Commercial
Operations (total turnover)
|
23,259
|
|
22,276
|
|
4
|
|
8
|
|
|
|
|
|
|
|
|
Operating
profit by segment
|
|||||||
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
12,012
|
|
11,044
|
|
9
|
|
14
|
Research and
Development
|
(4,055)
|
|
(3,876)
|
|
5
|
|
7
|
|
|
|
|
|
|
|
|
Segment
profit
|
7,957
|
|
7,168
|
|
11
|
|
17
|
Corporate and other
unallocated costs
|
(240)
|
|
(134)
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
operating profit
|
7,717
|
|
7,034
|
|
10
|
|
16
|
Adjusting
items
|
(4,392)
|
|
(862)
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
3,325
|
|
6,172
|
|
(46)
|
|
(41)
|
|
|
|
|
|
|
|
|
Finance
income
|
88
|
|
86
|
|
|
|
|
Finance
costs
|
(496)
|
|
(570)
|
|
|
|
|
Share
of after tax profit/(loss) of associates
and joint ventures
|
(3)
|
|
(4)
|
|
|
|
|
Profit/(loss) on
disposal of associates and joint ventures
|
–
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
2,914
|
|
5,685
|
|
(49)
|
|
(43)
|
|
|
|
|
|
|
|
Paid/
Payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
First
interim
|
11 July
2024
|
|
15
|
|
612
|
Second
interim
|
10
October 2024
|
|
15
|
|
612
|
Third
interim
|
9
January 2025
|
|
15
|
|
612
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
First
interim
|
13 July
2023
|
|
14
|
|
567
|
Second
interim
|
12
October 2023
|
|
14
|
|
568
|
Third
interim
|
11
January 2024
|
|
14
|
|
568
|
Fourth
interim
|
11
April 2024
|
|
16
|
|
652
|
|
|
|
|
|
|
|
|
|
58
|
|
2,355
|
|
|
|
|
|
|
|
|
Weighted
average number of shares
|
|
|
|
|
|||
|
Q3
2024
millions
|
|
Q3
2023
millions
|
|
9
months 2024
millions
|
|
9
months 2023
millions
|
|
|
|
|
|
|
|
|
Weighted average
number of shares – basic
|
4,080
|
|
4,055
|
|
4,076
|
|
4,050
|
Dilutive effect of
share options and share awards
|
61
|
|
57
|
|
61
|
|
58
|
|
|
|
|
|
|
|
|
Weighted average
number of shares – diluted
|
4,141
|
|
4,112
|
|
4,137
|
|
4,108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q3
2024
|
|
Q3
2023
|
|
9
months 2024
|
|
9
months 2023
|
|
2023
|
||
|
|
|
|
|
|
|
|
|
|
||
Average
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
US$/£
|
1.31
|
|
1.26
|
|
1.28
|
|
1.24
|
|
1.24
|
|
|
Euro/£
|
1.19
|
|
1.16
|
|
1.18
|
|
1.15
|
|
1.15
|
|
|
Yen/£
|
192
|
|
182
|
|
192
|
|
173
|
|
175
|
|
|
|
|
|
|
|
|
|
|
||
Period-end
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
US$/£
|
1.34
|
|
1.23
|
|
1.34
|
|
1.23
|
|
1.27
|
|
|
Euro/£
|
1.20
|
|
1.16
|
|
1.20
|
|
1.16
|
|
1.15
|
|
|
Yen/£
|
191
|
|
183
|
|
191
|
|
183
|
|
180
|
|
|
|
|
9
months 2024
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,718
|
|
6,662
|
Additions
|
–
|
|
104
|
Remeasurement
through income statement and other movements
|
1,106
|
|
1,294
|
Cash
payments: operating cash flows
|
(900)
|
|
(924)
|
Cash
payments: investing activities
|
–
|
|
(11)
|
|
|
|
|
Contingent
consideration at end of the period
|
5,924
|
|
7,125
|
|
|
|
|
9
months 2023
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,890
|
|
7,068
|
Remeasurement
through income statement and other movements
|
406
|
|
302
|
Cash
payments: operating cash flows
|
(834)
|
|
(853)
|
Cash
payments: investing activities
|
–
|
|
(7)
|
|
|
|
|
Contingent
consideration at end of the period
|
5,462
|
|
6,510
|
|
|
|
|
|
|
|
£m
|
|
|
|
|
Net
assets acquired:
|
|
|
|
Intangible
assets
|
|
|
886
|
Cash
and cash equivalents
|
|
|
23
|
Other
net liabilities
|
|
|
(16)
|
Deferred tax
liabilities
|
|
|
(188)
|
|
|
|
|
|
|
|
705
|
Goodwill
|
|
|
191
|
|
|
|
|
Total
consideration
|
|
|
896
|
Net debt information
|
Reconciliation
of cash flow to movements in net debt
|
|
|
|
|
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
|
|
|
Total
Net debt at beginning of the period
|
(15,040)
|
|
(17,197)
|
|
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
231
|
|
(340)
|
Increase/(decrease)
in liquid investments
|
(21)
|
|
(47)
|
Net
(increase)/repayment of short-term loans
|
1,410
|
|
(306)
|
Repayment of
long-term notes
|
–
|
|
(94)
|
Repayment of lease
liabilities
|
170
|
|
148
|
Net
debt of subsidiary undertakings acquired
|
–
|
|
50
|
Exchange
adjustments
|
504
|
|
304
|
Other
non-cash movements
|
(101)
|
|
(107)
|
|
|
|
|
(Increase)/decrease
in net debt
|
2,193
|
|
(392)
|
Total
Net debt at end of the period
|
(12,847)
|
|
(17,589)
|
Net
debt analysis
|
|
30
September 2024
£m
|
|
31
December 2023
£m
|
|
|
|
|
Liquid
investments
|
20
|
|
42
|
Cash
and cash equivalents
|
3,192
|
|
2,936
|
Short-term
borrowings
|
(2,815)
|
|
(2,813)
|
Long-term
borrowings
|
(13,244)
|
|
(15,205)
|
|
|
|
|
Total
Net debt at the end of the period
|
(12,847)
|
|
(15,040)
|
Free
cash flow reconciliation
|
|
Q3
2024
£m
|
|
Q3
2023
£m
|
|
9
months 2024
£m
|
|
9
months 2023
£m
|
|
|
|
|
|
|
|
|
Net
cash inflow/(outflow) from operating activities
|
2,154
|
|
2,212
|
|
4,225
|
|
3,572
|
Purchase of
property, plant and equipment
|
(305)
|
|
(299)
|
|
(855)
|
|
(828)
|
Proceeds from sale
of property, plant and equipment
|
1
|
|
11
|
|
4
|
|
21
|
Purchase of
intangible assets
|
(537)
|
|
(198)
|
|
(992)
|
|
(733)
|
Proceeds from
disposals of intangible assets
|
98
|
|
–
|
|
126
|
|
12
|
Net
finance costs
|
(13)
|
|
(11)
|
|
(294)
|
|
(397)
|
Dividends from
associates and joint ventures
|
–
|
|
–
|
|
15
|
|
1
|
Contingent
consideration paid (reported in investing activities)
|
(4)
|
|
(3)
|
|
(11)
|
|
(7)
|
Distributions to
non-controlling interests
|
(80)
|
|
(57)
|
|
(288)
|
|
(334)
|
Contributions from
non-controlling interests
|
8
|
|
–
|
|
9
|
|
7
|
|
|
|
|
|
|
|
|
Free
cash inflow/(outflow)
|
1,322
|
|
1,655
|
|
1,939
|
|
1,314
|
|
R&D
commentary
|
Pipeline
overview
|
Medicines and
vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
18
|
Infectious
Diseases (7)
|
|
●
|
Arexvy (RSV vaccine) RSV older adults
(18-59 years of age at increased risk (AIR))
|
||
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uncomplicated urinary tract
infection and urogenital gonorrhoea
|
||
●
|
bepirovirsen (HBV
ASO) hepatitis B virus
|
||
●
|
Bexsero infants vaccine
(US)
|
||
●
|
MenABCWY (gen 1)
vaccine candidate
|
||
●
|
tebipenem pivoxil
(antibacterial carbapenem) complicated urinary tract
infection
|
||
●
|
ibrexafungerp
(antifungal glucan synthase inhibitor) invasive
candidiasis
|
||
|
|
Respiratory/Immunology
(6)
|
|
|
|
●
|
Nucala (anti-IL5 biologic) chronic
obstructive pulmonary disease
|
|
|
●
|
depemokimab (ultra
long-acting anti-IL5 biologic) severe eosinophilic asthma,
eosinophilic granulomatosis with polyangiitis (EGPA), chronic
rhinosinusitis with nasal polyps (CRSwNP), hyper-eosinophilic
syndrome (HES)
|
|
|
●
|
latozinemab (AL001,
anti-sortilin) frontotemporal dementia
|
|
|
●
|
camlipixant (P2X3
receptor antagonist) refractory chronic cough
|
|
|
●
|
Ventolin (salbutamol, Beta 2 adrenergic
receptor agonist) asthma
|
|
|
●
|
linerixibat (IBATi)
cholestatic pruritus in primary biliary cholangitis
|
|
|
Oncology
(5)
|
|
|
|
●
|
Blenrep (anti-BCMA ADC) multiple
myeloma
|
|
|
●
|
Jemperli (anti-PD-1) 1L endometrial
cancer, colon cancer, rectal cancer, head and neck
cancer
|
|
|
●
|
Zejula (PARP inhibitor) 1L ovarian and
non-small cell lung cancer, glioblastoma
|
|
|
●
|
belrestotug
(anti-TIGIT) 1L non-small cell lung cancer
|
|
|
●
|
cobolimab
(anti-TIM-3) 2L non-small cell lung cancer
|
Total
vaccines and medicines in all phases of clinical
development
|
67
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
88
|
|
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
RSV
OA=ADJ-004
(Adults
≥ 60 years old)
NCT04732871
|
III
|
A
randomised, open-label, multi-country trial to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial
start:
Q1
2021
Primary
data reported:
Q2
2022
|
Active,
not recruiting; primary endpoint met
|
RSV
OA=ADJ-006
(ARESVI-006; Adults
≥ 60 years old)
NCT04886596
|
III
|
A
randomised, placebo-controlled, observer-blind, multi-country trial
to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial
start:
Q2
2021
Primary
data reported:
Q2
2022;
two
season data reported:
Q2
2023;
three
season data reported: Q3 2024
|
Complete; primary
endpoint met
|
RSV
OA=ADJ-007
(Adults
≥ 60 years old)
NCT04841577
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with FLU-QIV vaccine
in adults aged 60 years and above
|
Trial
start:
Q2
2021
Primary
data reported:
Q4
2022
|
Complete; primary
endpoint met
|
RSV
OA=ADJ-008
(Adults
≥ 65 years old)
NCT05559476
|
III
|
A phase
III, open-label, randomised, controlled, multi country trial to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU HD vaccine
in adults aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete; primary
endpoint met
|
RSV
OA=ADJ-009
(Adults
≥ 60 years old)
NCT05059301
|
III
|
A
randomised, double-blind, multi-country trial to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial
start:
Q4
2021
Trial
end:
Q2
2022
|
Complete; primary
endpoint met
|
RSV
OA=ADJ-017
(Adults
≥ 65 years old)
NCT05568797
|
III
|
A phase
III, open-label, randomised, controlled, multi-country trial to
evaluate the immune response, safety and reactogenicity of an
RSVPreF3 OA investigational vaccine when co-administered with FLU
aQIV (inactivated influenza vaccine – adjuvanted) in adults
aged 65 years and above
|
Trial
start:
Q4
2022
Primary
data reported:
Q2
2023
|
Complete; data
analysis ongoing
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
RSV
OA=ADJ-018
(Adults
50-59 years)
NCT05590403
|
III
|
A phase
III, observer-blind, randomised, placebo-controlled trial to
evaluate the non-inferiority of the immune response and safety of
the RSVPreF3 OA investigational vaccine in adults 50-59 years of
age, including adults at increased risk of respiratory syncytial
virus lower respiratory tract disease, compared to older adults
≥60 years of age
|
Trial
start:
Q4
2022
Primary
data reported:
Q4
2023
|
Complete; primary
endpoint met
|
RSV
OA=ADJ-019
(Adults
≥ 60 years old)
NCT05879107
|
III
|
An
open-label, randomised, controlled, multi-country trial to evaluate
the immune response, safety and reactogenicity of RSVPreF3 OA
investigational vaccine when co-administered with PCV20 in adults
aged 60 years and older
|
Trial
start:
Q2
2023
Data
anticipated:
H2
2024
|
Complete
|
RSV
OA=ADJ-023
(Immunocompromised
Adults 50-59 years)
NCT05921903
|
IIb
|
A
randomised, controlled, open-label trial to evaluate the immune
response and safety of the RSVPreF3 OA investigational vaccine in
adults (≥50 years of age) when administered to lung and renal
transplant recipients comparing one versus two doses and compared
to healthy controls (≥50 years of age) receiving one
dose
|
Trial
start:
Q3
2023
Primary
data reported:
Q4
2024
|
Active,
not recruiting; primary endpoint met
|
RSV-OA=ADJ-020
(Adults
aged >=50 years of age)
NCT05966090
|
III
|
A study
on the safety and immune response of investigational RSV OA vaccine
in combination with herpes zoster vaccine in healthy
adults
|
Trial
start:
Q3
2023
Primary
data reported:
Q3
2024
|
Active,
not recruiting; primary endpoint met
|
RSV-OA=ADJ-013
(Adults
aged 50 years and above)
NCT06374394
|
III
|
An
open-label, randomized, controlled study to evaluate the immune
response, safety and reactogenicity of RSVPreF3 OA investigational
vaccine when co-administered with a COVID-19 mRNA
vaccine
|
Trial
start:
Q2
2024
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
RSV
OA=ADJ-025
(Adults, 18-49
years of age, at increased risk for RSV disease and older adults
participants, >=60 YOA)
NCT06389487
|
IIIb
|
An
open-label study to evaluate the non-inferiority of the immune
response and to evaluate the safety of the RSVPreF3 OA
investigational vaccine in adults 18-49 years of age at increased
risk for Respiratory Syncytial Virus disease, compared to older
adults >=60 years of age
|
Trial
start:
Q2
2024
Primary
data reported:
Q4
2024
|
Active,
not recruiting; primary endpoint met
|
RSV
OA=ADJ-021
(Adults
aged 60 years and above)
NCT06551181
|
III
|
A study
on the immune response, safety and the occurrence of Respiratory
Syncytial Virus (RSV)-associated respiratory tract illness after
administration of RSV OA vaccine in adults 60 years and
older
|
Trial
start:
Q3
2024
Data
anticipated:
H2
2025
|
Recruiting
|
RSV
OA+ADJ-012
(Adults
aged 60 years and above)
NCT06534892
|
|
An
Extension and Crossover Vaccination Study on the Immune Response
and Safety of a Vaccine Against Respiratory Syncytial Virus Given
to Adults 60 Years of Age and Above Who Participated in RSV
OA=ADJ-006 Study
|
Trial
start: Q3 2024
Data
anticipated: 2026
|
Recruiting
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
B-Well
1 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630807
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
Data
anticipated: 2026+
|
Active,
not recruiting
|
B-Well
2 bepirovirsen in nucleos(t)ide treated patients (chronic hepatitis
B)
NCT05630820
|
III
|
A
multi-centre, randomised, double-blind, placebo-controlled trial to
confirm the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial
Start:
Q1
2023
Data
anticipated: 2026+
|
Active,
not recruiting
|
bepirovirsen
sequential combination therapy with targeted
immunotherapy
(chronic hepatitis
B)
NCT05276297
|
II
|
A trial
on the safety, efficacy and immune response following sequential
treatment with an anti-sense oligonucleotide against chronic
hepatitis B (CHB) and chronic hepatitis B targeted immunotherapy
(CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA)
therapy
|
Trial
start:
Q2
2022
Data
anticipated: 2026+
|
Active,
not recruiting
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
EAGLE-1
(uncomplicated urogenital gonorrhoea)
NCT04010539
|
III
|
A
randomised, multi-centre, open-label trial in adolescent and adult
participants comparing the efficacy and safety of gepotidacin to
ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhoea caused by Neisseria gonorrhoeae
|
Trial
start:
Q4
2019
Data
reported:
Q1
2024
|
Complete;
primary
endpoint met
|
EAGLE-2
(females with uUTI / acute cystitis)
NCT04020341
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q4
2019
Data
reported:
Q2
2023
|
Complete; primary
endpoint met
|
EAGLE-3
(females with uUTI / acute cystitis)
NCT04187144
|
III
|
A
randomised, multi-centre, parallel-group, double-blind,
double-dummy trial in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial
start:
Q2
2020
Data
reported:
Q2
2023
|
Complete; primary
endpoint met
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
MenABCWY –
019
NCT04707391
|
IIIb
|
A
randomised, controlled, observer-blind trial to evaluate safety and
immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial
start:
Q1
2021
Data
reported:
Q1
2024
|
Complete, primary
endpoints met
|
MenABCWY –
V72 72
NCT04502693
|
III
|
A
randomised, controlled, observer-blind trial to demonstrate
effectiveness, immunogenicity, and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
Data
reported:
Q1
2023
|
Complete; primary
endpoints met
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
CALM-1
(refractory chronic cough)
NCT05599191
|
III
|
A
52-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q4
2022
Data
anticipated:
H2
2025
|
Recruiting
|
CALM-2
(refractory chronic cough)
NCT05600777
|
III
|
A
24-week, randomised, double-blind, placebo-controlled, parallel-arm
efficacy and safety trial with open-label extension of camlipixant
in adult participants with refractory chronic cough, including
unexplained chronic cough
|
Trial
start:
Q1
2023
Data
anticipated:
H2
2025
|
Recruiting
|
(*)
|
As the pooled analysis of SWIFT-1 and SWIFT-2 did
not control for multiple comparisons, results with a significant
p-value (>0.05) are termed nominally
significant.
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
SWIFT-1
(severe eosinophilic asthma)
NCT04719832
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Complete; primary
endpoint met
|
SWIFT-2
(severe eosinophilic asthma)
NCT04718103
|
III
|
A
52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre trial of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial
start:
Q1
2021
Data
reported:
Q2
2024
|
Complete; primary
endpoint met
|
AGILE
(SEA)
NCT05243680
|
III
(exten
sion)
|
A
52-week, open label extension phase of SWIFT-1 and SWIFT-2 to
assess the long-term safety and efficacy of depemokimab adjunctive
therapy in adult and adolescent participants with severe
uncontrolled asthma with an eosinophilic phenotype
|
Trial
start:
Q1
2022
Data
anticipated:
H1
2025
|
Active,
not recruiting
|
NIMBLE
(SEA)
NCT04718389
|
III
|
A
52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority trial assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial
start:
Q1
2021
Data
anticipated:
H2
2025
|
Active,
not recruiting
|
ANCHOR-1 (chronic
rhinosinusitis with nasal polyps; CRSwNP)
NCT05274750
|
III
|
Efficacy and safety
of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported: Q3 2024
|
Complete; primary
endpoint met
|
ANCHOR-2
(CRSwNP)
NCT05281523
|
III
|
Efficacy and safety
of depemokimab in participants with CRSwNP
|
Trial
start:
Q2
2022
Data
reported:
Q3
2024
|
Complete; primary
endpoint met
|
OCEAN
(eosinophilic granulomatosis with polyangiitis; EGPA)
NCT05263934
|
III
|
Efficacy and safety
of depemokimab compared with mepolizumab in adults with relapsing
or refractory EGPA
|
Trial
start:
Q3
2022
Data
anticipated:
2026+
|
Recruiting
|
DESTINY
(hyper-eosinophilic syndrome; HES)
NCT05334368
|
III
|
A
52-week, randomised, placebo-controlled, double-blind, parallel
group, multicentre trial of depemokimab in adults with uncontrolled
HES receiving standard of care (SoC) therapy
|
Trial
start:
Q3
2022
Data
anticipated:
2026+
|
Recruiting
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
MATINEE
(chronic obstructive pulmonary disease; COPD)
NCT04133909
|
III
|
A
multicentre randomised, double-blind, parallel-group,
placebo-controlled trial of mepolizumab 100 mg subcutaneously as
add-on treatment in participants with COPD experiencing frequent
exacerbations and characterised by eosinophil levels
|
Trial
start:
Q4
2019
Data
reported:
Q3
2024
|
Active,
not recruiting; primary endpoint met
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
DREAMM-7 (2L+
multiple myeloma; MM)
NCT04246047
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of the combination of belantamab mafodotin, bortezomib,
and dexamethasone (B-Vd) compared with the combination of
daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial
start:
Q2
2020
Primary
data reported:
Q4 2023
|
Primary
endpoint met
|
DREAMM-8 (2L+
MM)
NCT04484623
|
III
|
A
multi-centre, open-label, randomised trial to evaluate the efficacy
and safety of belantamab mafodotin in combination with pomalidomide
and dexamethasone (B-Pd) versus pomalidomide plus bortezomib and
dexamethasone (P-Vd) in participants with relapsed/refractory
multiple myeloma
|
Trial
start:
Q4
2020
Primary
data reported:
Q1
2024
|
Primary
endpoint met
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
RUBY
(1L stage III or IV endometrial cancer)
NCT03981796
|
III
|
A
randomised, double-blind, multi-centre trial of dostarlimab plus
carboplatin-paclitaxel with and without niraparib maintenance
versus placebo plus carboplatin-paclitaxel in patients with
recurrent or primary advanced endometrial cancer
|
Trial
start:
Q3
2019
Part 1
data reported:
Q4
2022
Part 2
data reported:
Q4
2023
|
Active,
not recruiting; primary endpoints met
|
PERLA
(1L metastatic non-small cell lung cancer)
NCT04581824
|
II
|
A
randomised, double-blind trial to evaluate the efficacy of
dostarlimab plus chemotherapy versus pembrolizumab plus
chemotherapy in metastatic non-squamous non-small cell lung
cancer
|
Trial
start:
Q4
2020
Primary
data reported:
Q4
2022
|
Active,
not recruiting; primary endpoint met
|
GARNET
(advanced solid tumours)
NCT02715284
|
I/II
|
A
multi-centre, open-label, first-in-human trial evaluating
dostarlimab in participants with advanced solid tumours who have
limited available treatment options
|
Trial
start:
Q1
2016
Primary
data reported:
Q1
2019
|
Recruiting
|
AZUR-1
(locally advanced rectal cancer)
NCT05723562
|
II
|
A
single-arm, open-label trial with dostarlimab monotherapy in
participants with untreated stage II/III dMMR/MSI-H locally
advanced rectal cancer
|
Trial
start:
Q1
2023
Data
anticipated: 2026+
|
Active,
not recruiting
|
AZUR-2
(untreated perioperative T4N0 or stage III colon
cancer)
NCT05855200
|
III
|
An
open-label, randomised trial of perioperative dostarlimab
monotherapy versus standard of care in participants with untreated
T4N0 or stage III dMMR/MSI-H resectable colon cancer
|
Trial
start:
Q3
2023
Data
anticipated: 2026+
|
Recruiting
|
COSTAR
Lung (advanced non-small cell lung cancer that has progressed on
prior PD-(L)1 therapy and chemotherapy)
NCT04655976
|
II/III
|
A
multi-centre, randomised, parallel group treatment, open label
trial comparing cobolimab + dostarlimab + docetaxel to dostarlimab
+ docetaxel to docetaxel alone in participants with advanced
non-small cell lung cancer who have progressed on prior
anti-PD-(L)1 therapy and chemotherapy
|
Trial
start:
Q4
2020
Data
anticipated:
H1
2025
|
Active,
not recruiting
|
JADE
(locally advanced unresected head and neck cancer)
NCT06256588
|
III
|
A
randomised, double-blind, study to evaluate dostarlimab versus
placebo as sequential therapy after chemoradiation in participants
with locally advanced unresected head and neck squamous cell
carcinoma
|
Trial
start:
Q1
2024
Data
anticipated: 2026+
|
Recruiting
|
|
|
|
|
|
Trial
name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
ZEAL-1L
(1L advanced non-small cell lung cancer maintenance)
NCT04475939
|
III
|
A
randomised, double-blind, placebo-controlled, multi-centre trial
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial
start:
Q4
2020
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
FIRST
(1L ovarian cancer maintenance)
NCT03602859
|
III
|
A
randomised, double-blind, comparison of platinum-based therapy with
dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
non-mucinous epithelial ovarian cancer
|
Trial
start:
Q4
2018
Data
anticipated:
H2
2024
|
Active,
not recruiting
|
|
|
●
|
the
income statement and statement of comprehensive income for the
three and nine month periods ended 30 September 2024 on page 26 and
27;
|
●
|
the
balance sheet as at 30 September 2024 on page 28;
|
●
|
the
statement of changes in equity for the nine-month period then ended
on page 29;
|
●
|
the
cash flow statement for the nine-month period then ended on page
30; and
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 31 to 43 that
have been prepared applying consistent accounting policies to those
applied by GSK plc and its subsidiaries (“the Group”)
in the Annual Report 2023, which was prepared in accordance with
International Financial Reporting Standards (“IFRS”) as
adopted by the United Kingdom.
|
|
GSK
plc
|
|
(Registrant)
|
|
|
Date: October
30, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|